The weather: Low stimulation, open sky, physical movement, natural beauty, time - and solitude, or a small trusted group.

There is a particular quality of intention that brings people to nature rather than to a festival. Not intensity, but depth. Not dissolution into a crowd, but a quieter loosening - of the grip of the everyday, of the noise that accumulates in ordinary life, of the sense that the self is a fixed and separate thing. The motivations are harder to name than the festival’s collective effervescence, but they are no less real: reconnection, awe, reflection, the specific relief of being somewhere that does not require you to perform.

There is also something pharmacologically distinctive about this context that is worth naming before the substances. The body is already engaged - moving, breathing, responding to uneven ground and changing light. The senses are already heightened by an environment that did not need to be designed to produce that effect. The ordinary social pressures that shape most altered state experiences - the crowd, the music, the implicit expectation of a certain kind of experience - are largely absent. What remains is the landscape, the body moving through it, and whatever the mind brings.

For some people, psychoactive substances are part of how they amplify that. Understanding which ones serve that intention - and which quietly work against it - is what this post is about.

The Oldest Context

Before harm reduction literature, before randomised controlled trials, before the word psychedelic existed, there was this: a person, a plant, and the natural world. The oldest documented contexts for psychedelic use are not clinical rooms or festival fields. They are forests, mountains, deserts, and riverbanks. The Mazatec mushroom ceremonies of Oaxaca, the peyote rituals of the Native American Church, the ayahuasca traditions of the Amazon basin - all developed in relationship with the natural world rather than apart from it. This is not incidental. It is structural. The medicines and the environment were understood, across traditions and centuries, to be working together. [1]

The neuroscience is beginning to catch up with what these traditions understood empirically. The predictive processing framework - introduced in the second post of this Substack - helps explain why. Classic psychedelics loosen the brain’s top-down predictions, allowing more of the raw sensory signal to flood through. In a high-stimulation environment like a festival, that loosening meets an already overwhelming sensory field. In a natural environment, it meets something different: a landscape that is complex and alive, but not chaotic. The brain, temporarily freed from its ordinary filters, encounters the texture of bark, the movement of light through leaves, the sound of water - and processes them with an intensity and freshness that most adults have not felt since childhood. The environment is not a backdrop to the pharmacology. It is part of it. [2]

The Environment

If the environment is an active ingredient, then the specific topography dictates the psychological boundaries of the experience. Natural settings exist on a spectrum of cognitive demand, and matching the landscape to an altered state is a foundational, though rarely discussed, safety variable.

Familiar, bounded spaces - a quiet woodland path, a secluded clearing, or a gentle, well-marked trail you have walked dozens of times before - are the most protective. These environments offer what environmental psychologists call “soft fascination”: a landscape rich in non-threatening sensory inputs, like the movement of leaves or shifting light, that gently anchors an open mind without demanding active problem-solving.

Conversely, high-stakes or unpredictable topographies introduce an unacceptable operational risk. Exposed ridges, coastal cliffs, fast-moving water, or dense, trail-less backcountry require an acute, continuous physical vigilance. A landscape that demands you actively survive it is fundamentally incompatible with a loosened state of consciousness. The goal should be to choose a setting that holds the experience, rather than one that tests your capacity to endure it.

The Taxonomy of the Trail

Classic Psychedelics

Psilocybin mushrooms, LSD and mescaline are perhaps the most consistently reported substance-context fit in the user literature - and the fit is not accidental. The heightened sensory perception, the loosening of the boundary between self and world, the sense of interconnectedness with the natural environment: these effects find their fullest expression outdoors. Scoping reviews of harm reduction strategies for psychedelic users consistently identify natural settings and controlled social environments as among the most protective contextual factors available. [3]

The dose question is more consequential here than in almost any other context - and the figures that follow are starting points rather than prescriptions. Body weight, prior experience, tolerance, and the potency of the specific batch all shift the picture considerably. At low to moderate doses - one to 1.5 grams of dried psilocybin mushrooms, or 25 to 75 micrograms of LSD - the experience tends to remain participatory: the walker stays oriented, engaged with the environment, capable of navigating and responding to what arises [4, 5]. The natural world feels more vivid, more present, more alive. A dose that reads as mild for one person may be fully immersive for another. Outdoors, where navigation and physical coordination are not optional, that difference matters in ways it simply does not in a living room.

At higher doses, the picture changes significantly. Psychometric dose-response data show that positive subjective effects plateau at around 100 µg LSD, while anxiety and ego dissolution increase sharply above it - and a natural environment offers none of the structured support that makes navigating that territory safe. [5, 6] Unpredictable weather, remote locations, and terrain that demands physical coordination are variables that compound rather than cushion a difficult experience. Harm reduction practitioners are consistent: high-dose psychedelic experiences require a stable, predictable setting — which the outdoors, by definition, is not. [3] Getting lost in the woods is complicated enough without the trees actively trying to speak with you.

Timing is the variable that experienced users most consistently flag, and that beginners most consistently underestimate [4, 6]. Psilocybin at a moderate dose runs four to six hours; LSD from 8 to 12. Starting early enough in the day to be well into the descent before darkness falls is not a minor consideration. The shift from daylight to night mid-experience introduces a variable that many users report as significantly altering the character of the experience - not always in welcome ways. The quality of light, the temperature, the sounds of a landscape at night are all different enough from the daytime environment to constitute, in effect, a change of setting mid-experience. Plan for the full duration, not just the peak.

Having a trusted person present, even at a distance, significantly reduces the risk of adverse outcomes. Agreeing in advance on a simple check-in system - a message at a specific time, a meeting point, a clear signal for if something goes wrong - is one of the most practical harm reduction steps available in this context, and one of the least discussed. Solo use in remote natural environments is not a neutral choice. It is a variable that amplifies every other risk in the picture. [3]

Microdosing

Sub-perceptual doses of psilocybin or LSD - typically one tenth to one twentieth of a full dose - are frequently reported in user communities as enhancing presence, sensory awareness, and emotional openness in natural environments. The anecdotal literature on microdosing in nature is extensive and remarkably consistent in its enthusiasm.

It is worth being precise about what the controlled evidence actually shows. The most rigorous study to date found that reported benefits were largely indistinguishable from placebo under blinded conditions, suggesting that expectation effects play a significant role. [7] A subsequent systematic review found that while some studies report modest positive effects on convergent thinking and wellbeing, overall effect sizes remain small and methodologically vulnerable to placebo expectations, leading authors to urge caution about overclaiming. [8] The long-term risks of repeated low-level serotonin 2A receptor stimulation remain poorly understood. The subjective reports are consistent and widespread; the controlled evidence is considerably more cautious. Both things can be true - and in a publication committed to honesty, both things need to be said.

What the evidence does support is this: for people who report that microdosing enhances their experience of being outdoors, the harm profile at genuinely sub-perceptual doses is low, provided the substance has been accurately tested and the dose carefully measured. The risk, in practice, is less the pharmacology than the imprecision - a dose intended as sub-perceptual that turns out to be perceptual, in an environment that requires navigation and physical coordination, when the person did not prepare for it, is a different proposition entirely.

Uppers / Stimulants

Stimulants as a category tend to find little purchase in this context. What a walk in nature asks for is presence - a quality of attention that turns outward and slows down. Most uppers are optimised for the opposite direction: inward focus, acceleration, the compression of time rather than its expansion. The pharmacological contrast is measurable: where classic psychedelics reduce ratings of concentration and speed of thinking while expanding sensory awareness, stimulants do precisely the reverse. [9] Cocaine’s hyper-alert self-focus is a poor pharmacological fit for a landscape that rewards surrender rather than control. MDMA is not a great fit for a quiet walk in the woods either - unless, of course, you happen to be walking toward an underground rave. Where it does appear in outdoor contexts, the harm reduction considerations are acute: MDMA disrupts thermoregulation, and the combination of physical exertion, variable weather, and a substance that impairs the body’s ability to regulate its own temperature can be a dangerous triad [10].

Caffeine is the partial exception. A coffee before a long walk is not a harm reduction concern - for many, it is breakfast. The caveat, as always in physically demanding contexts, is hydration: caffeine’s mild diuretic effect, combined with physical exertion and variable weather, is worth being conscious of on a long day out.

Dissociatives

Dissociatives like ketamine and nitrous oxide represent the ultimate ecological mismatch for this context. A walk in nature is a study in sensory connection and motor adaptation - it requires the nervous system to continuously coordinate movement over uneven ground while processing real external signals. Dissociatives operate in the precise opposite direction, severing top-down motor control and replacing the sensory field with internal, unanchored abstraction.

The safety hazards are immediate: attempting to navigate uneven ground while experiencing the balance disruption and spatial disorientation of ketamine carries a real risk of physical injury. Nitrous oxide, with its brief but intense postural instability, is similarly mismatched with a landscape defined by rocks and roots. If the goal of being outdoors is to ground the conscious mind in a living ecosystem, a class of compounds that detaches the mind from the body is a poor fit for the path.

Cannabis

Cannabis at low doses is widely reported by users as deepening sensory awareness and appreciation of natural environments - making colours more vivid, sounds more textured, and the experience of simply being outside feel more fully inhabited. [4] For many people, a walk in nature is precisely the context in which cannabis finds its most natural expression: the reduced social pressure, the sensory richness of the environment, and the physical movement all tend to work with the substance rather than against it.

The dose-dependence operates sharply in both directions, and this is worth stating plainly. Slightly too much, particularly in open or exposed environments, can tip quickly into anxiety or paranoia - a risk that is meaningfully amplified by the high-potency products that dominate the current market. There is a very fine line between feeling at one with nature and feeling like the local wildlife is actively judging your life choices. Low and slow is the consistent recommendation, and it applies with particular force here. [4]

One practical note specific to this context that harm reduction literature rarely addresses directly: cannabis and navigation do not always combine well. The cognitive softening that makes the substance pleasant in a familiar space - the loosening of linear thought, the drift toward associative rather than directed attention - can become a genuine liability when the landscape demands precise map reading, scrambling, or route-finding in unfamiliar terrain. Know the route before, not during. If the path involves any genuine navigational challenge, cannabis has no place on it until the terrain has been entirely negotiated, the return is over, and you are safely off the trail.

The specific choice of cannabis interacts sharply with the demands of the landscape. Heavy, sedating indica varieties can introduce a physical lethargy that turns a moderate incline into a distinct struggle against gravity. Sativa-dominant varieties offer a more appropriate brightness for physical movement, but they carry their own outdoor caveat: a blend that is high in THC and low in CBD can easily amplify the anxiety or unease that wide-open spaces can provoke. For an active landscape, the most balanced approach is to prioritize a high-CBD, low-THC ratio. This can be achieved either by selecting a pre-balanced variety or simply by blending a small amount of standard high-THC cannabis with a generous portion of CBD-only flower. The ratio is worth paying attention to before you set out, rather than after.

Alcohol

Alcohol is also a poor pharmacological fit for this context, and the case against it here is more straightforward than in most settings. The physical sedation, cognitive blunting, and dehydration that alcohol reliably produces work directly against what most people are seeking in a natural environment. [11, 12a, 12b] There is also a safety consideration that harm reduction literature rarely states plainly enough: alcohol impairs balance, coordination and judgement in ways that carry real physical risk in uneven terrain. Falls, exposure, and navigational errors are all meaningfully more likely under its influence.

There is also a subtler cost that sits outside the usual frame of individual risk. Alcohol increases impulsivity and erodes the attentive, considered behaviour that most people who walk in nature regard as a basic obligation - leave no trace, carry out what you carried in, close the gate behind you. Anyone who has walked a popular trail on a Sunday morning has encountered the evidence: cans stacked with misplaced tidiness on a tree stump, abandoned bottles at viewpoints, the quiet archaeology of the previous day’s poor decisions. The landscape does not distinguish between accidental and careless. It simply absorbs what is left behind.

The long walk in the hills deserves better chemistry - and if the honest answer is that the walk is less appealing without a drink, that is worth sitting with rather than solving pharmacologically.

The Material Anchor

There is an entirely practical variable that the user literature flags far more consistently than clinical trials: what you carry in your pack. A walk in nature demands physical energy, but under the influence of certain substances, the relationship with sustenance shifts. Experienced users of LSD and cannabis frequently note that the sensory enhancement extends sharply to taste, turning ordinary food into a surprisingly profound experience on the descent; packing an appropriate quantity of food - and being prepared for it to taste absurdly good - is a basic tenet of the outdoor trip. Water, however, belongs to the category of absolute necessity rather than sensory pleasure [12]. If the day involves MDMA or any mild stimulant, the combination of physical movement, altered temperature regulation, and chemical dehydration makes a generous water supply a primary safety constraint. You can afford to miscalculate your appetite; you cannot afford to miscalculate your hydration. The elements do not care about your expanded consciousness.

Beyond sustenance, the technology you rely on to navigate the landscape demands a layer of backup that sober walking rarely requires. A smartphone is the default map, but batteries drain rapidly in cold weather or areas with poor cellular signal, and bright sunlight can make interfaces illegible when your pupils are fully dilated. Rather than relying on live signal, the practical approach is downloading offline maps before leaving, putting the phone on airplane mode to preserve the battery, and tossing a small, fully charged portable power bank into your pack. If the terrain requires actual woodcraft or a compass to survive, it is the wrong terrain for this context entirely.

But even gentle terrain requires planning for the weather you might encounter, not just the weather currently visible through the trees. Because psychedelics can disrupt your body’s internal thermostat - leaving you suddenly shivering in mild air or overheating on a minor incline - extra layers and a windproof or waterproof shell are essential. Adding a space blanket into the bottom of the pack takes up virtually no room, but it drastically lowers the stakes if an afternoon descent takes longer than planned. In the backcountry, harm reduction is often indistinguishable from basic outdoor preparedness.

The Non-Pharmacological Argument

It would be incomplete to write about nature as a context for altered states without acknowledging what the research on nature itself now shows - independent of any substance.

Time spent in natural environments has been associated in multiple studies with reduced cortisol levels, lower amygdala reactivity, improved mood, and restored attentional capacity. [13] Shinrin-yoku - the Japanese practice of forest bathing, which involves slow, mindful immersion in a forest environment without any particular destination or goal - has been the subject of many controlled studies, with consistent findings of reduced stress hormones, lower blood pressure, and improved immune function. [14] These are not placebo effects. They are measurable physiological responses to a specific kind of environment.

For a population overwhelmingly confined to indoor spaces, screen interfaces, and the artificial stillness of desk work, this counterweight is no longer a luxury - it is a physiological necessity. Modern urban existence demands a continuous, highly directed form of attention while offering little in the way of physical grounding or sensory complexity. A walk in nature interrupts that specific, cumulative exhaustion. It restores the body to its evolutionary baseline: moving through three-dimensional space, adjusting to uneven terrain, and engaging with an environment that asks nothing of you except that you inhabit it.

The implication for this series is one that runs through every post: the altered state that nature produces on its own - the softening of our top-down cognitive habits, the loosening of self-referential thought, the heightened sensory awareness - overlaps meaningfully with what psychedelics produce pharmacologically. Nature is not a neutral backdrop. In this context, it is an active ingredient - sometimes the most important one.

A Note on Solitude and Company

The question of whether to walk alone or with others is also worth addressing directly, because it shapes the experience in ways that go beyond simple safety - and because the answer is less obvious than it might appear.

Solitude in nature - particularly with a psychedelic - tends to turn the experience inward. Without the social anchoring that another person provides, the mind moves more freely into its own territory: memory, emotion, the kind of associative thinking that does not happen in conversation. This can be precisely what someone is seeking, and when it goes well, it goes very well. Experienced users sometimes seek exactly this - a deliberate, prepared encounter with their own inner landscape, held by the natural world rather than by another person.

But experience, however extensive, cannot account for what cannot be predicted. A twisted ankle on uneven ground, an unexpected change in weather, a psychological turn that arrives faster and harder than anticipated - these are not failures of preparation. They are the irreducible unpredictability of being a body in a landscape under a substance that loosens the ordinary filters of perception and self-protection. No amount of previous experience eliminates that variable. It only changes how well you can navigate it when it arrives - and navigation is considerably harder alone.

A small trusted group - ideally three or four people who know each other well, who have discussed intentions in advance, and who are comfortable with silence - is meaningfully safer than solitude, and tends to produce a richer experience rather than a lesser one. The key word is trusted: people who can hold space without filling it, who will not panic if the experience becomes difficult, and who understand that silence is not a problem to be solved. Crucially, the safest version of this context includes at least one person who is not tripping and whose primary role is to remain oriented, to hold the practical thread of the day, and to be genuinely available if something goes wrong. This is not a diminished role. In many traditions, it is the most important one.

Large groups introduce the social dynamics of the festival into a context that was not designed for them. The natural environment’s capacity to ground and support the experience diminishes as the group grows and the social complexity increases. Two or three is a fundamentally different proposition from ten - not just in degree, but in kind.

The forest does not know you have taken anything. It offers the same damp earth, the same shifting light, the same slow indifference to your interior weather - whether you arrive with an amplified mind, your everyday self or ordinary fatigue. That is, in some ways, the most useful thing about it. The experience it makes possible is not dependent on the substances this post has discussed. It only asks that you show up, slow down, and pay attention. The compounds, when used carefully and occasionally, can help with that. So can leaving them at home.

The next post in this series will move indoors - into the private, intimate context of an evening at home with a romantic partner. Having mapped the collective and the solitary, we turn to the most personal territory of all.

References

[1] Schultes, R.E. & Hofmann, A. (1979). Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Healing Arts Press.

[2] Carhart-Harris, R.L. & Friston, K.J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344.

[3] Dutton, C., North, E., Chun Tie, Y., Oliva, J. & Skeffington, P. (2025). Harm reduction practices for users of psychedelic drugs: a scoping review. Harm Reduction Journal, 22, 158.

[4] Erowid. Erowid.org: The most comprehensive community archive of first-person psychoactive experience reports available. Not a clinical source, but an invaluable record of lived experience at scale - particularly useful for understanding dose norms, duration, and context effects as reported by experienced users.

[5] Holze, F., Vizeli, P., Ley, L. et al. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 46, 537–544.

[6] Liechti, M.E. (2017). Modern Clinical Research on LSD. Neuropsychopharmacology, 42(11), 2114–2127.

[7] Szigeti, B. et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife, 10, e62878.

[8] Szigeti, B. et al. (2023). Microdosing psychedelics: a systematic review of the evidence. Neuroscience & Biobehavioral Reviews.

[9] Holze, F. et al. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology, 45, 462–471.

[10] Freedman, R.R., Johanson, C.E. & Tancer, M.E. (2005). Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology, 183, 248–256.

[11] Fillmore, M.T. (2003). Alcohol tolerance in humans: psychomotor effects. Current Drug Abuse Reviews.

[12] Hobson, R.M. & Maughan, R.J. (2010). Hydration status and the diuretic action of a small dose of alcohol. Alcohol and Alcoholism, 45(4), 366–373.

[12b] Masento, N.A. et al. (2014). Effects of hydration status on cognitive performance and mood. British Journal of Nutrition, 111(10), 1841–1852.

[13] Bratman, G.N. et al. (2015). Nature experience reduces rumination and subgenual prefrontal cortex activation. Proceedings of the National Academy of Sciences, 112(28), 8567–8572.

[14] Li, Q. (2010). Effect of forest bathing trips on human immune function. Environmental Health and Preventive Medicine, 15(1), 9–17.

Further Reading

On the history of psychedelics in natural and indigenous contexts Schultes, R.E. & Hofmann, A. (1979). Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Healing Arts Press. The foundational ethnobotanical account of psychedelic plant use across indigenous cultures. Schultes spent decades in the Amazon documenting traditions that Western science had barely registered. The book that established that the natural world and psychedelic experience have been in relationship for as long as humans have.

On the neuroscience of nature and wellbeing Bratman, G.N. et al. (2015). Nature experience reduces rumination and subgenual prefrontal cortex activation. Proceedings of the National Academy of Sciences, 112(28), 8567–8572. The study that put the neuroscience of nature on the map - demonstrating that time in natural environments measurably reduces the kind of self-referential, ruminative thinking associated with depression. Short, readable, and directly relevant to everything this post argues about nature as an active ingredient rather than a neutral backdrop.

On forest bathing Li, Q. (2018). Forest Bathing: How Trees Can Help You Find Health and Happiness. Viking. The most accessible account of the shinrin-yoku research by one of its leading investigators. Li’s summary of over a hundred controlled studies makes the case that immersion in forest environments produces measurable physiological benefits that go well beyond what relaxation alone would predict.

On microdosing Szigeti, B. et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife, 10, e62878. The most methodologically rigorous study of microdosing to date - and the most honest about what the evidence does and does not show. Essential reading for anyone whose enthusiasm for microdosing has outrun their familiarity with the controlled evidence.

On harm reduction for psychedelic users Dutton, C., North, E., Chun Tie, Y., Oliva, J. & Skeffington, P. (2025). Harm reduction practices for users of psychedelic drugs: a scoping review. Harm Reduction Journal, 22, 158. The most current and comprehensive review of harm reduction strategies specifically for psychedelic users. Particularly relevant to the nature context: the sections on setting, social support and preparation are directly applicable to everything this post covers.

On the predictive processing account of psychedelics Carhart-Harris, R.L. & Friston, K.J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. The paper behind the neuroscientific framework used throughout this series. Technical in places but worth the effort - the REBUS model is the most coherent current account of why set and setting are not peripheral to the psychedelic experience but central to it.

The experience was real. The insight was real. But there was nothing underneath it to hold the weight.

This is not an argument against psychedelic experiences. It is an observation about what they require to land. We are living through an extraordinary moment of renewed interest in the therapeutic and transformative potential of psychoactive substances - and that interest is, in many respects, justified by the evidence. But the conversation that has accompanied it has developed a significant blind spot: a tendency to focus on the experience itself while paying considerably less attention to the life the experience is returning to. The container matters. But so does what the container is sitting on.

This post is about what that something underneath needs to be. It is also, honestly, about what no substance - however carefully chosen, however wisely used - can build for you.

The Body Budget

The neuroscientist Lisa Feldman Barrett has spent decades dismantling one of the most persistent myths in popular psychology: that emotions are things that happen to you, fixed biological responses triggered by events in the world. Her research tells a different story. Emotions are constructed - built, moment by moment, by a brain that is constantly predicting what the body will need next and preparing it accordingly. [1]

The concept she uses to describe this is the body budget - admittedly not the most poetic of metaphors, but one that earns its keep. In the technical literature it goes by the less memorable name of allostasis. Your brain is running a continuous metabolic accounting system, tracking the resources your body has spent and anticipating what it will need: energy, water, safety, social connection, rest. When the budget is well-managed - when you are sleeping, eating, moving, and feeling genuinely connected to other people - the brain has the raw material to construct emotions that are varied, flexible, and proportionate to what is actually happening. When the budget is chronically in deficit, the brain constructs from scarcity: the emotional range narrows, threat detection becomes hyperactive, and the capacity for nuance - for curiosity, for joy, for genuine connection - quietly contracts. [1, 2]

This perspective has a direct implication for anyone thinking seriously about psychoactive substances and mental health: a depleted body budget is not a substrate that any drug can reliably fix. What it can do - and what it often does - is temporarily mask the deficit while the underlying account continues to drain.

The Floor

Sleep is the most non-negotiable item on the budget. Matthew Walker’s summary of the evidence is unambiguous: there is no major psychiatric condition in which sleep is normal, and the causal arrows run in both directions - poor mental health disrupts sleep, and disrupted sleep actively generates poor mental health. [3] A single night of significant sleep deprivation measurably increases amygdala reactivity - part of the brain’s threat-detection system - by up to 60%. The emotional world of a sleep-deprived person is not the same emotional world as a rested one: it is narrower, louder, and more frightened.

It is also worth acknowledging that sleeping well is harder than it has ever been. Current work cultures routinely normalise schedules that are structurally incompatible with adequate rest. And the devices most people carry into their bedrooms are engineered by some of the most sophisticated behavioural science in history, with algorithms explicitly designed to extend engagement at the cost of everything else, including sleep. Blue light from screens suppresses melatonin production; the emotional activation of social media and news keeps the nervous system in a state of alert that is the opposite of what sleep requires. Being informed about basic sleep hygiene practices is, in this environment, a genuine act of self-protection: avoiding caffeine after early afternoon, reducing screen exposure in the hour before bed, keeping the bedroom free of screens entirely, and protecting a consistent sleep and wake time even at weekends. None of this is complicated - all of it is harder than it sounds in a world designed to work against it.

Food is less discussed in mental health contexts than it deserves to be, partly because the research is newer and partly because nutritional psychiatry sits awkwardly between disciplines that rarely talk to each other. But the evidence is accumulating: ultra-processed diets are associated with significantly elevated rates of depression and anxiety; the gut-brain axis is not a wellness industry invention but a genuine bidirectional communication system; and the brain, which runs on roughly 20% of the body’s total energy despite being 2% of its weight, is acutely sensitive to the quality of what it is given to work with. [4]

It is worth acknowledging that making consistently healthy food choices is genuinely difficult - not a matter of willpower or awareness alone. Despite growing public consciousness about nutrition, the majority of food available in most supermarkets is ultra-processed and nutritionally poor. Whole, minimally processed food tends to be more expensive, less convenient, and requires a level of planning and effort that fits poorly with the pace of modern life. This is a structural failure, not a personal one - and any honest conversation about food and mental health has to hold both the evidence and the reality of the environment most people are actually navigating.

Movement is the intervention with perhaps the most robust evidence base of all. Regular physical exercise has been shown in meta-analyses to be as effective as antidepressants for mild to moderate depression - not as a replacement for medication in severe cases, but as a genuine first-line intervention that most people are never offered. [5] The mechanisms are multiple: neurogenesis in the hippocampus, regulation of the HPA stress axis, increased BDNF, improved sleep architecture, and - perhaps most importantly for Barrett’s framework - a direct, reliable way of spending and replenishing the body budget that does not require any external substance at all. The form it takes matters less than the consistency: walking, swimming, dancing, cycling, yoga - the research is largely agnostic about which, and strongly in favour of all of them.

A structural gap in this evidence base deserves honest acknowledgment. The research on sleep, nutrition and movement has been built predominantly on male subjects - a bias that runs through biomedical science more broadly and that has particular consequences here. Hormonal cycles profoundly shape all three: sleep architecture changes across the menstrual cycle, with the luteal phase associated with disrupted sleep and increased emotional sensitivity; nutritional needs and appetite regulation shift with hormonal fluctuation; and motivation and capacity for movement also fluctuate significantly across the cycle - with the follicular phase typically associated with higher energy and exercise tolerance, and the luteal phase with reduced motivation, increased fatigue and longer recovery times. The research on how these interactions affect mental health, and how they should inform harm reduction advice for women who use psychoactive substances, remains thin. Any honest account of this topic has to acknowledge that the blueprint we are working from has historically neglected half the population.

These three - sleep, food, movement - are the floor. They are not glamorous. They do not produce the kind of experiences people describe as transformative or transcendent. They do not make good stories at dinner. But they are what makes everything else possible. A substance taken into a body that is chronically sleep-deprived, poorly nourished, and sedentary is not meeting the same brain as one taken into a body that is rested, fed, and physically alive. The pharmacology is identical. The substrate is not.

A cultural phenomenon worth naming clearly: the same years that have seen a renaissance of interest in psychedelics have also produced a growing wellness culture in which sleep, nutrition and movement have become almost obsessive practices - and in which all psychoactive substances, legal or otherwise, are often treated as equally incompatible with a healthy life. The floor these practices build is real and valuable. But the conclusion that no substance has any place in a well-lived life does not follow from the evidence — and it reproduces, from a different direction, the same binary thinking that drug prohibition produced from the other side. Just say no has many dialects.

The Emotional Repertoire

Barrett makes a second argument that deserves as much attention as the body budget, and receives considerably less. She calls it emotional granularity - the size and precision of the vocabulary, both linguistic and experiential, that a person has for their own inner states. [1]

The research finding is striking: people who have a richer, more differentiated emotional vocabulary - who can distinguish between feeling anxious and feeling apprehensive, between grief and disappointment, between contentment and joy - are measurably better at regulating those states. The brain, which constructs emotion partly from concept and language, has more precise tools to work with. The person who can only identify that they feel bad is working with a blunt instrument. The person who can identify that they feel ashamed of something specific, in a way that is asking them to act differently, has already begun the process of responding to it.

This is where practices that extend the emotional repertoire become, in the most literal neurological sense, a form of mental health intervention. Reading literary fiction - which requires the sustained inhabitation of another person’s inner life - has been shown to increase theory of mind and emotional complexity. [6] Journaling, particularly expressive writing about difficult experiences, has a well-documented effect on psychological integration and immune function. [7] Therapy, when it works, works partly by giving people new concepts for their own experience - new ways of constructing what they feel that are more accurate, more differentiated, and more actionable than the ones they arrived with.

None of this requires a substance. All of it deepens what a substance, used wisely, might occasionally catalyse. The insight that arrives during a psychedelic experience does not integrate itself. It requires a mind that has the conceptual vocabulary to receive it, and the reflective practices to work with it over time. The experience opens a door. The emotional repertoire determines whether you can walk through it.

A word on integration - a concept that has become central to the psychedelic community’s vocabulary, and that contains real wisdom alongside a significant blind spot. When someone has a significant psychedelic experience and finds, months later, that little has changed, the explanation most commonly offered is that they failed to integrate properly - that more journaling, more meditation, more therapy would have consolidated what the experience opened. This framing is not wrong, exactly - but it is incomplete in a way that matters. Integration practices are valuable. They are not, however, a substitute for the floor. Someone who is chronically sleep-deprived, poorly nourished, and socially isolated is not going to yoga their way to lasting change on the basis of a single experience - however profound. The insight lands on depleted ground. The practices that matter most are not the ones that follow the experience: they are the ones that were already in place before it arrived.

The Most Important Variable

In 1938, Harvard University began following a group of 268 undergraduate men across their entire adult lives - tracking their health, their relationships, their careers, and their happiness decade by decade - a cohort that reflected the exclusions of its era, and that has since been expanded to include women, the original participants’ children, and a broader cohort from Boston’s inner city. The study has had multiple directors across nearly ninety years. Its current director, the psychiatrist Robert Waldinger, summarised its central finding in a wonderful book called The Good Life: Lessons from the World’s Longest Scientific Study of Happiness. [8]

The main finding is this: the quality of a person’s close relationships is the single strongest predictor of health and happiness across the lifespan. Not wealth. Not professional achievement. Not IQ. Not even physical health in early adulthood. The people who were most satisfied in their relationships at fifty were the healthiest at eighty. Loneliness, conversely, was found to be as damaging to long-term health as smoking fifteen cigarettes a day. [8, 9]

One question from the study has stayed with me since I first encountered it. At one point, participants were asked: who could you call in the middle of the night if you were sick or scared? The people who could list several names were, consistently, the happiest and the healthiest. Some - including some who were married - could not list a single one. Waldinger’s conclusion is simple: everyone needs at least one person like that. [8]

This finding has been replicated across multiple longitudinal datasets, across cultures, and across very different definitions of what a good relationship looks like. The mechanism runs, again, directly through Barrett’s framework: social connection is one of the most powerful regulators of the body budget there is. A trusted other person - someone whose presence signals safety to the nervous system - is doing something that no substance can replicate: they are co-regulating your physiology in real time, reducing the metabolic cost of simply being alive.

I have seen this in clinical practice and I have seen it in the communities I am part of. The people who navigate altered states most gracefully - who integrate difficult experiences, who use substances as tools rather than escapes, who return from wherever they have been with something they can actually use - are almost always people who have somewhere to return to. A relationship, a community, a web of genuine connection that was there before the experience and is still there after it.

And the reverse is equally true, and equally important to name. Substances used in ways that damage relationships - that erode trust, create secrecy, or pull someone away from the people closest to them - are doing harm that no pharmacological benefit can offset. Some do this slowly and invisibly. Others do it acutely: certain substances increase impulsivity and aggression in ways that are well documented and painfully familiar - capable of turning an ordinary evening into something that takes weeks to repair, or doesn’t repair at all. Others still do it through absence rather than conflict: a creeping dissociation from the present moment, from the people in the room, from the emotional availability that relationships require to stay alive. The most important argument for harm reduction is not, ultimately, about neurotoxicity or addiction potential. It is about this: the choices people make around substances are among the most consequential choices they make for their relationships - and their relationships are the most consequential thing in their lives.

This is why harm reduction education matters. Not primarily because it reduces the risk of a bad trip or a dangerous drug interaction - though it does both of those things. But because it gives people the knowledge to make choices that serve their connections rather than undermine them. A person who understands what MDMA does to serotonin over time is better placed to use it in ways that deepen intimacy rather than chase it compulsively. A person who understands what alcohol actually does - to inhibition, to memory, to the quality of presence - is better placed to decide how much of it they want in their closest relationships. Knowledge is not a guarantee of good choices. But ignorance is a guarantee of uninformed ones.

Where Drugs Actually Fit

None of this is an argument against psychoactive substances: it is an argument for their correct place in the picture.

Used wisely - with knowledge, intention, a well-maintained body budget, a developed emotional vocabulary, and a relational life worth returning to - certain substances can genuinely amplify what is already there.

Research suggests that MDMA, used occasionally and carefully, can open emotional territory that years of ordinary conversation have not reached. A double-blind study in healthy volunteers found that it significantly increased feelings of closeness, friendliness and empathy, alongside reduced fear and defensiveness in social interactions. [10] A naturalistic survey found that MDMA use was associated with increased positive and affiliative language when people talked about significant others - suggesting its relational effects extend beyond the acute experience into how people think and speak about the people closest to them. [11]

Psilocybin tells a similarly relational story. In Griffiths and colleagues’ landmark 2006 study of healthy volunteers, a single high dose occasioned experiences that participants rated among the most personally meaningful of their lives. Strikingly, family members independently reported that they observed sustained increases in empathy and positive social behaviour in the participants, in the weeks that followed. [12] A 2026 survey of 581 naturalistic psychedelic users found that over 80% reported at least one major life change influenced by their psychedelic use - changes in values, social activities, goals and relationships - rated as overwhelmingly positive. [13]

Cannabis, used with attention to THC/CBD balance and context, is widely reported in user literature and survey studies as easing social connection, amplifying sensory experience and expanding creative associations - though the scientific literature consistently notes that very frequent use is associated with reduced wellbeing over time, a distinction that matters. [14, 15, 16]

But amplify is the operative word. These substances work on what exists. Some of them might show you the stars. They cannot build the floor.

The floor is built slowly, unglamorously, and without ceremony: in the quality of sleep you protect, the food you eat, the way you move your body, the books that expand your inner vocabulary, the journal you return to, and above all, in the relationships you tend with the same care and attention you might bring to anything else you consider important.

That is where the work is. Everything else - including the most remarkable substance ever synthesised - is, at best, a well-chosen tool in a life that was already worth living.

As always, nothing here constitutes medical advice. If you are navigating a mental health condition or concerns about substance use, please seek support from a qualified professional.

Drugs, Honestly publishes monthly deep dives on harm reduction, consciousness, and the honest relationship between psychoactive substances and the good life. If this resonated, share it with someone who needs it - or with someone you simply want to have this conversation with.

References

[1] Barrett, L.F. (2017). How Emotions Are Made: The Secret Life of the Brain. Houghton Mifflin Harcourt.

[2] Sterling, P. (2012). Allostasis: A model of predictive regulation. Physiology & Behavior, 106(1), 5–15.

[3] Walker, M. (2017). Why We Sleep: Unlocking the Power of Sleep and Dreams. Scribner.

[4] Jacka, F.N. et al. (2017). A randomised controlled trial of dietary improvement for adults with major depression. BMC Medicine, 15, 23.

[5] Schuch, F.B. et al. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51.

[6] Kidd, D.C. & Castano, E. (2013). Reading literary fiction improves theory of mind. Science, 342(6156), 377–380.

[7] Pennebaker, J.W. & Beall, S.K. (1986). Confronting a traumatic event: Toward an understanding of inhibition and disease. Journal of Abnormal Psychology, 95(3), 274–281.

[8] Waldinger, R. & Schulz, M. (2023). The Good Life: Lessons from the World’s Longest Scientific Study of Happiness.Simon & Schuster.

[9] Holt-Lunstad, J., Smith, T.B. & Layton, J.B. (2010). Social relationships and mortality risk: A meta-analytic review. PLOS Medicine, 7(7), e1000316.

[10] Dumont, G.J.H. et al. (2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Social Neuroscience, 4(4), 359–366.

[11] Baggott, M.J. et al. (2016). Intimate insight: MDMA changes how people talk about significant others. Journal of Psychopharmacology, 30(7), 669–677.

[12] Griffiths, R.R., Richards, W.A., McCann, U. & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268–283.

[13] Aday, J.S., Glynos, N.G., Baker, A.K. et al. (2026). Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically. Scientific Reports, 16, 17493.

[14] Erowid. Erowid.org: Documenting the Complex Relationship Between Humans and Psychoactives. — The largest archive of first-person accounts of psychoactive substance use on the internet. Not peer-reviewed and not without bias, but an irreplaceable record of lived experience that formal pharmacology rarely captures. Best read critically and comparatively rather than as a source of dosing guidance.

[15] Johnson-Ferguson, L., Loher, M., Bechtiger, L. et al. (2025). Cannabis use is associated with changes in psychological and functional well-being during young adulthood: evidence from self-reports and hair analyses. Psychological Medicine, 55, e246. https://doi.org/10.1017/S003329172510144X

[16] Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, Wall MM, Keyes KM, Martins SS. Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016. JAMA Psychiatry. 2020 Feb 1;77(2):165-171.

Further Reading

On the neuroscience of emotion and the body budget Barrett, L.F. (2017). How Emotions Are Made: The Secret Life of the Brain. Houghton Mifflin Harcourt. The scientific foundation for everything this post argues about emotional construction and the body budget. Barrett’s central claim - that emotions are not things that happen to you but things your brain actively builds from available resources - is one of the most important ideas in contemporary neuroscience, and one of the least absorbed by popular culture. The chapter on body budgeting alone is worth the price of the book.

Barrett, L.F. (2020). Seven and a Half Lessons About the Brain. Houghton Mifflin Harcourt. A shorter, more accessible companion to How Emotions Are Made - nine brief essays that cover the same conceptual territory in a fraction of the reading time. The lesson on the brain as a body-budgeting organ is the one to start with. Ideal for anyone who wants the argument without the full scientific apparatus.

On sleep Walker, M. (2017). Why We Sleep: Unlocking the Power of Sleep and Dreams. Scribner. The most comprehensive popular account of sleep science available, and the book most likely to permanently change your relationship with the eight hours you have been treating as optional. Walker’s central argument - that there is no major organ or process in the brain that is not enhanced by sleep and damaged by its absence - is stated with a confidence that some researchers have questioned at the margins. The core message, however, is not in dispute: sleep is the most powerful single intervention available for mental and physical health, and most people in industrialised societies are chronically short of it.

On relationships and happiness Waldinger, R. & Schulz, M. (2023). The Good Life: Lessons from the World’s Longest Scientific Study of Happiness. Simon & Schuster. The book that emerged from eighty-five years of the Harvard Study of Adult Development - the most sustained attempt ever made to answer the question of what actually makes a human life go well. The finding is both simple and consistently underestimated: the quality of your close relationships predicts your health, your happiness, and the length of your life more reliably than any other variable measured. Required reading for anyone who has ever prioritised achievement over connection and wondered, later, whether that was the right trade.

On expressive writing and emotional processing Pennebaker, J.W. & Evans, J.F. (2014). Expressive Writing: Words That Heal. Idyll Arbor Press. Pennebaker’s accessible guide to the practice that emerged from his decades of research. The finding that writing about difficult experiences for as little as fifteen minutes, three or four times, produces measurable improvements in physical health and psychological integration is one of the most replicated results in psychology - and one of the most underused. This is the practical companion to the research referenced in the post.

On nutritional psychiatry Jacka, F. (2019). Brain Changer: The Good Mental Health Diet. Macmillan Australia. The most accessible entry point into the emerging field of nutritional psychiatry, written by one of its leading researchers. Jacka’s work - including the SMILES trial, the first randomised controlled trial to demonstrate that dietary improvement can treat clinical depression - makes the case that what we eat is not peripheral to mental health. It is one of its primary determinants. A field that did not exist twenty years ago and is now producing some of the most important results in psychiatry.

On exercise and mental health Ratey, J.J. & Hagerman, E. (2008). Spark: The Revolutionary New Science of Exercise and the Brain. Little, Brown. The most readable account of what exercise actually does to the brain - not the body, the brain. Ratey’s argument, built on two decades of neuroscience, is that physical movement is the single most powerful tool available for improving mood, attention, and cognitive function, and that the mental health benefits of exercise have been systematically underestimated by a medical culture that treats the brain and body as separate systems. The chapter on depression is particularly relevant to everything this post argues.

The weather: High stimulation, large crowds, loud music, physical exertion, heat, sleep deprivation, emotional intensity, strangers becoming friends.

To understand the modern music festival is to recognise it not as a novel invention of late-stage capitalism or 1960s counterculture, but as a contemporary expression of one of the oldest human needs. The sociologist Émile Durkheim called it collective effervescence - the synchronised energy that arises when a community gathers for a shared purpose. Something shifts when bodies move together in time, when sound becomes a shared physical experience rather than a private one, when the ordinary boundaries between self and crowd begin to dissolve. Festivals are collective biological events, and they have been deliberately cultivated by human societies for as long as there have been human societies [1, 2].

Yet, a look across the tides of history reveals a striking pattern: many of these grand gatherings, once central to the rhythms of life, have vanished - lost to the shifts of religious conquest, political anxiety, and modernization.

In ancient Greece, the Dionysian Mysteries allowed citizens to shed their rigid societal roles through ecstatic dance and music. In Rome, the Floralia welcomed spring with brightly colored clothing and unrestrained, joyful mischief, while Saturnalia served as a winter carnival where social norms flipped - masters served slaves, and rigid hierarchies dissolved into gleeful chaos. Even the medieval church had to tolerate the Feast of Fools, a spectacle of wild parody and social inversion where clergy and commoners swapped roles in mock services [3]. Across indigenous cultures globally, repetitive drumming, communal dancing, and the intentional use of psychoactive plants have served for millennia as technologies for boundary dissolution and renewal.

Why do some traditions endure while others slip quietly into obscurity? Historically, ruling classes and religious institutions have consistently feared the uncontrollable, anti-hierarchical nature of the crowd. The Feast of Fools was eventually aggressively banned by church officials; along with Kyoto’s Gion Matsuri and France’s Festival of the Supreme Being [3, 4]. When thousands of people gather in a dusty field today, dancing before a towering wall of speakers, they are stepping directly into this contested lineage - whether they know it or not. They are reclaiming a human rite that society has repeatedly tried to civilize, suppress, or forget.

The ancient festival, however, was embedded in a web of shared meaning: ritual structure, community elders, collective preparation, and an explicit cultural grammar for what the experience was for. Many modern festivals have largely shed that scaffolding - arriving instead as commercial products, weekend events, and standardized commodities. But this is not the whole picture.

A significant strand of contemporary festival culture has consciously attempted to rebuild exactly that kind of ancient container: community-organized gatherings rooted in ecological values, consent culture, harm reduction infrastructure, and an explicit intention to create something more than an entertainment marketplace. Some have gone further still, establishing dedicated psychological crisis support - “psycare” services staffed by trained volunteers able to provide a calm space and human presence for those navigating difficult experiences. They remain, unfortunately, a minority of events, though their numbers appear to be growing.

The transformational festival movement, the free party tradition, and many smaller regional gatherings operate from a fundamentally different set of values than the commercial megafestival - and that difference is not merely aesthetic. It shapes the physical environment, the social norms, and the psychological safety available to people navigating altered states within them.

The risk, in either case, is the same: the altered states on offer - whether accessed through music, movement, or chemistry - are many times navigated without maps, without guides, and without the kind of social knowledge that once made such experiences legible [5]. This is not an argument for nostalgia - it is an observation about the value of preparation, which is precisely what this piece is for.

The Modern Festival

The modern festival has diverged into distinct sub-genres - from the anonymous scale of the megafestival to the intimate container of the small boutique gathering, from the continuous electronic pulse of the rave to the explicitly psychedelic orientation of the transformational festival. These distinctions matter immensely for harm reduction: the physical environment, the social dynamics, and the psychological container are all different, and they interact with psychoactive substances in meaningfully different ways.

It is entirely possible, of course, to navigate a multi-day festival completely sober - or to rely on the standard portfolio of Western, prohibition-escaping drugs: flooding the system with caffeine to survive the morning, burning through nicotine to manage the social anxiety of the afternoon, and drowning the evening in alcohol. But as many find out by day three, this capitalism-sanctioned cocktail is an incredibly punishing and limited way to experience the landscape.

It is also worth noting why so many people abruptly stop attending festivals in mid-adulthood. It is rarely because they suddenly lost their love of music, dancing, or communal joy - more often, it is because they made a series of uninformed pharmacological choices in their youth or early adulthood, pushed their bodies and minds past the brink in unsupportive environments, suffered the inevitable neurochemical fallout, and mistakenly concluded that the festival itself was the problem.

For those who choose to bring chemistry into it, knowing which substances serve the environment - and which undermine it - is what this post is about.

The Molecules in the Field

Caffeine is the festival’s most reliable morning companion - and one of the least discussed in harm reduction literature, possibly because it is so embedded in ordinary life that its psychoactive status barely registers. To put it bluntly: yes, your grandmother has been doing psychoactive drugs this entire time. The average kitchen counter is essentially a low-stakes apothecary, which masks the fact that we are dealing with a powerful central nervous system stimulant. The adenosine antagonism that produces alertness and focus is a reasonable tool for a day that will make significant demands on the body and mind. By blocking adenosine receptors, it temporarily prevents the accumulation of sleep pressure, tricking the brain into a state of vigilant readiness.

However, the harm reduction note that festival contexts make more consequential than usual: caffeine is a stimulant and a diuretic, and combining it with heat, physical exertion, and other stimulants creates a dehydration and cardiovascular load that is worth being conscious of. [6, 7] A coffee in the morning and another after lunch is not a risk worth dramatising. Three or four coffees, an energy drink, and four hours of dancing in the sun is a different calculation. When layered on top of the residual vasoconstriction of the previous night’s substances, that afternoon iced latte can be the tipping point that transforms standard festival fatigue into an uncomfortable, jittery anxiety that is difficult to shake off in a dense crowd.

MDMA is a substance whose relationship with a specific strand of festival culture is not incidental - it is foundational [8] The acid house and rave movement that shaped the modern electronic music festival was built around it: the empathogenic effect, the dissolution of social barriers, the heightened response to repetitive beats and collective movement - echoing, in ways that are more than superficial, the role of rhythm and altered states in ancient ritual cultures [9, 10] - were not accidental features of the scene but its pharmacological engine.

By flooding the synaptic cleft with serotonin, MDMA commonly creates a profound state of emotional openness. The temporary down-regulation of the amygdala allows users to navigate social spaces entirely free of baseline anxiety, mapping directly onto the festival environment in ways that are well documented in the harm reduction literature.

Direct fatal overdose from MDMA alone is rare, but the indirect risks in a festival context are not: hyperthermia, hyponatraemia, and overstimulation are all amplified by heat, exertion and crowds [14, 20], which is why organisations like The Loop and Kosmicare place particular emphasis on dose, hydration and rest in festival harm reduction work. Harm reduction guidelines recommend ensuring that any substance has been properly tested before use, starting with a weighed dose of roughly 100-120 mg (ideally 1.5 mg/kg of body weight), taking no more than a quarter of any pill, ensuring that any booster dose does not exceed half of the initial amount and waiting at least ninety minutes before considering more. The earlier the last dose is taken, the less circadian rhythms are disrupted, reducing the chances of mood drop on the days after. Avoiding taking MDMA every day of a festival is also an obvious principle - unless your goal is to spend the next Tuesday having an existential crisis over a dropped piece of toast.

In the festival ecosystem, classic psychedelics are commonly used to expand it, rather than escaping it. In user literature, a low dose of psilocybin (1 to 1.5g of dried mushrooms) or LSD (25–75 micrograms) is frequently described as a tool for amplifying sensory immersion, emotional openness, and increasing connection with both the music and the surrounding crowd. At these low-dose thresholds, the standard moderate-high dose psychedelic “trip” is replaced by an enhanced appreciation for acoustic textures and an empathetic alignment with collective movement, allowing the individual to remain participatory rather than internal. Low-dose mescaline is similarly reported as highly manageable, offering a mildly stimulating, uniquely grounded experience centered on presence that integrates smoothly with the celebratory atmosphere of a long festival day, particularly if taken in the morning. It is also worth stating clearly: contrary to others substances, fatal overdose from classic psychedelics alone is not a documented risk - the risks here are psychological and contextual rather than physiological.

Timing, however, remains the critical variable for balancing energy levels across a multi-day event. Because of the molecule’s long duration, introducing an 8-to-12-hour substance like LSD after sunset often means anchoring oneself to an altered state well into the cold clarity of dawn. This extends the experience into the intense final hours of the night, leaving attendees to navigate the harsh sensory transition of a waking campground, or simply trading vital sleep architecture for a prolonged, restless comedown.

A high dose of classic psychedelics in the same environment is a very different proposition: the unpredictability of a festival environment becomes a significant variable in an already complex internal experience. Although taking 300 micrograms of acid at once on purpose at a festival is rare, a common situation is taking a blotter with unknown dosage (never a good idea), or taking a low dose, feeling no effects after one hour, and deciding to take more - a classic beginner’s mistake. Harm reduction practitioners consistently advise that high-dose psychedelic experiences require a stable, predictable setting - which a festival, by definition, is not [18]. The literature on psychedelic research is unambiguous on this point: the container is not incidental to the experience [5, 11-13]. It is part of it.

2C-B is frequently reported in festival and club contexts in user literature - its combination of mild visual enhancement, physical energy, and sociability without the long duration of LSD makes it a commonly reported fit for a festival evening. [22] Developed by Alexander Shulgin in the 1970s, it acts primarily as a partial agonist at the 2A serotonin receptor, but with a distinct pharmacological profile that leaves the user’s conceptual, analytical mind remarkably intact. Unlike MDMA, it does not force open the emotional floodgates: its effects are less empathogenic and more sensory - the experience tends toward the perceptual, the tactile, and the physical rather than the emotionally connective, which is worth knowing before rather than discovering mid-experience.

The steep dose-response curve is the consistent harm reduction priority: the difference between a manageable, sparkly vibrancy and an overwhelming hallucinogenic experience is a matter of just a few milligrams. A dose of 10-15 mg might provide a light, texturized energy akin to a clean stimulant, while 20-25 mg can plunge the user into a kaleidoscopic, deeply shifting visual landscape. Because a festival environment - with its informal dosing, unknown pill strengths, and social pressure - is not a forgiving context for getting that wrong, accurate testing and measurement is paramount. [22] Onset can also take anywhere from 45 to 90 minutes orally, making premature redosing a particular risk.

Cannabis is one of the most commonly used substances at festivals and concerts, widely reported as deepening the musical experience - particularly in quieter moments or at the end of the night. For many, that is exactly the point: cannabis is used at festivals not to alter the experience dramatically, but to soften the edges of it - to make the music feel closer, the crowd less overwhelming, the moment more inhabitable. Users also frequently report that it can expand lateral thinking and associative creativity - making conversations stranger and funnier, music more layered, and the general absurdity of several thousand people in a field together become a source of genuine, lighthearted philosophical wonder.

Yet, maintaining this gentle headspace requires deliberate effort in a modern festival setting. The consistent caveat in harm reduction literature is that large crowds and high-THC cannabis are a frequently reported combination for anxiety and paranoia, particularly for those with existing vulnerabilities. [19] This is worth stating plainly: a festival is not a good place to try cannabis for the first time; the setting simply amplifies whatever the substance initiates. Even for experienced users, the high-potency products that dominate the current market make cautious dosing essential. Increasingly, contemporary festival-goers navigate this by blending traditional cannabis with CBD-only varieties, utilizing CBD’s natural antipsychotic and calming properties to anchor the experience and buffer against THC’s edge-inducing effects.

For those who chose to camp within vibrating distance of the main stage, relying on sheer willpower to sleep is a bold strategy. Historically, cannabis has served as a sort of universal language - the common ground where festival tribes who otherwise prefer entirely different substances can meet to wind down. It is widely reported by users as helpful for sleep in an environment that makes it difficult, with indica strains favoured by their ability to mute the chaos. Given the impossibility of overdose, many harm reduction practitioners consider it considerably safer in this role than benzodiazepines, provided the person has an established and predictable relationship with the plant. The emphasis, however, belongs on predictable - the same properties that make it useful for winding down can, with too much THC or not enough experience, make a noisy festival feel like a very long and very strange night.

Alcohol is culturally ubiquitous at festivals and undeniably effective: it reduces social anxiety, lowers defenses, and is genuinely responsible for a vast amount of festival laughter and shared fun. Yet, it is one of the most pharmacologically mismatched substances for the environment. It is dehydrating, physically taxing, cognitively impairing, and the substance most consistently associated with violence and interpersonal conflict in festival harm reduction data. [15] It is also, unlike other substances in this list, capable of fatal overdose in its own right - acute alcohol poisoning remains one of the most under-acknowledged risks at festivals precisely because the substance is legal and socially normalised.

Furthermore, many festival-goers reflexively drink while taking MDMA or psychedelics, oblivious to the fact that alcohol actively dampens the precise psychoactive effects - the empathy, the clarity, the vivid sensory expansion - they were seeking in the first place. This creates a dulled, muddy experience that often drives users to take higher, riskier doses of both substances to compensate.

The compounding bill for this cross-fade arrives the next morning. The standard hangover is violently magnified in a festival setting; waking up in a baking plastic tent, already depleted, only to face another twelve hours of intense sensory input is a brutal compounding of physical and mental exhaustion. Drinking at a multi-day festival is a sure way of ensuring the journey home feels less like a post-festival wind-down and more like a psychological thriller. Indeed, one of the most common errors born from a lack of drug education occurs in the aftermath of these events: completely shattered by a combination of polydrug use and heavy drinking, many individuals vow to “stop doing drugs” while entirely giving alcohol a free-pass. They return to standard drinking, sometimes heavily, oblivious to the fact that it was the alcohol that drove the bulk of their neurochemical and physical bankruptcy.

In my time working with psychological crisis support services at festivals, GHB is consistently recognized as the single most dangerous substance on site in terms of acute, fatal overdose. The pharmacological trap is its notoriously unforgiving dose-response curve: the window between the desired euphoric, alcohol-like effects and full respiratory depression is razor-thin. Because it is almost always distributed as a clear liquid, accurate dosing without a syringe or standardized pipette is virtually impossible. Compounding this risk is its catastrophic interaction with alcohol; combining the two is a direct route to unconsciousness. In the medical tents, GHB is treated as a high-stakes guessing game where losing the bet means stopping breathing.

Because of this, the only advice that truly matters in a festival setting is peer surveillance. If someone in your camp is using GHB, they cannot be left alone. If they become unresponsive or slip into what looks like a heavy sleep, you cannot assume they are just “sleeping it off” - they need to be placed in the recovery position, their airway checked, and medical staff alerted immediately. In this context, looking out for your friends isn’t just a festival etiquette; it is the line between a rough morning and a tragedy.

Ketamine, crushed from crystals into an inhaled powder, has become increasingly common at festivals. The appeal is real and worth naming: ketamine offers a rapid, controllable dissociation from the noise and overwhelm of a festival - a brief exit from the crowd, the heat, the stimulation. Users also frequently describe a distinctly altered experience of electronic music (particularly ambiend and dubstep) under its influence: rhythm, space and time are perceived differently, in ways that many find fascinating rather than simply numbing.

Dissociation in a crowded, high-stimulation environment, however, carries real physical risk - falls, disorientation, and a significantly reduced ability to recognise or respond to danger. Despite this, the substance has developed such an aura of safety that declining it can require a surprising amount of social courage - especially when a Californian shaman is looking you in the eye and insisting it’s a sacred medicine.

Part of this aura stems from a marketing myth: its theoretical absence of a next-day chemical hangover. While a single dose might leave the morning intact, the reality of festival use is dictated by compulsive redosing, which the drug’s short duration actively encourages. By chasing the high into the early morning hours, users routinely trade a chemical hangover for a circadian one - completely disrupting their sleep architecture and waking up depleted. The other risks that warrant serious attention are the longer-term consequences of heavy use: psychological dependence and, in chronic users, severe and sometimes irreversible bladder damage. [16] Fatal overdose from ketamine alone is possible at high doses - a fact that sits awkwardly with its reputation as the safe option. Those doses do not have to arrive in a single administration; cumulative toxicity can build across a night of redosing without the user registering it as escalation. The more acute risk in practice is stopped or dangerously slowed breathing (respiratory depression), which can arrive rapidly and without warning, particularly when combined with other substances. These are not theoretical risks. They are well-documented in the literature about recreational use of ketamine and increasingly visible in harm reduction settings. The question worth sitting with before the first line is whether the context you’re in is one of intentional celebration - or dissociation from it.

The draw of cocaine is equally understandable: energy, confidence, sociability, the feeling of being switched on in an environment that rewards all three. In a setting partly built around presence and performance, those effects have an obvious appeal. However, short duration combined with inevitable redosing, physical exertion and heat creates a cardiovascular risk profile that harm reduction practitioners flag consistently. [15, 17] At high doses or in combination with other stimulants, cocaine carries a real risk of cardiac arrest - a risk that heat, physical exertion, and sleep deprivation meaningfully amplify.
It is a drug engineered for aggressive individualism, creating a hyper-focused, self-absorbed headspace that completely clashes with the collective, shared vibe of a festival. The short-lived high quickly turns the experience into a stressful, full-time job of hunting for the next bag in a dark tent, pulling the user away from the music and into their own frantic loop - and the mood crash that follows lands in an environment that offers little support for it.

Cacao - specifically the ceremonial preparations increasingly common in festival wellness spaces - occupies a genuinely interesting middle ground in the psychoactive spectrum. The theobromine and phenylethylamine it contains produce a mild, warm stimulation that many users report as grounding and gently heart-opening, and its harm profile is negligible for most people. [21] It is not a powerful psychoactive substance - and the more extravagant claims sometimes made for it in wellness contexts deserve the same honest scrutiny this piece applies elsewhere. But it is not pharmacologically inert either, and in a festival context its gentle, connective quality makes it one of the more benign ways of marking a transition in the day - from morning to afternoon, from rest to movement.

One category has been deliberately omitted from this guide: novel psychoactive substances - 2-MMC, 3-MMC, m-cat, 5-APB, 6-APB, synthetic cannabinoids, and the broader NPS landscape. The reasoning is simple: in an environment already placing significant demands on the body and mind, reaching for a substance with no established safety data and unknown long-term effects is a risk with no corresponding reward. The case for avoiding them is made in the first post of this Substack, and will be subject of a deep dive soon - but the practical harm reduction principle is this: avoid substances younger than you.

Structure and Spontaneity

Navigating a multi-day festival requires shifting one’s mindset from a single-night sprint to a physiological marathon. While a discrete evening of altered consciousness carries a predictable footprint, layering substances across consecutive days introduces an entirely different order of compounding risk. A frequent mistake is the repetitive use of the same class of substance day after day. This practice triggers a rapid down-regulation of receptors; neurochemical tolerance blunts the desired euphoric or expansive effects, forcing the user to chase a receding high with higher doses, which exponentially elevates the risk of toxic or adverse physical events - as well as worsening next-day hangover/comedown effects. Experienced festival-goers navigate this biological ceiling by treating their time as a curated arc - intentionally alternating between entirely different classes of molecules and, crucially in longer festivals, interspersing dedicated, substance-free days to allow their neurochemistry to stabilize and breathe.

Ultimately, however, the most foundational harm-reduction infrastructure is entirely non-pharmacological. No amount of precise chemical measurement can outrun the systemic bankruptcy of food deprivation, severe dehydration, and shattered sleep cycles. The true anchors of endurance are deceptively mundane: eating dense meals, aggressive hydration, protecting windows of actual sleep, and moving within a tight, reliable web of peers who actively look out for one another’s well-being. It is also why the rise of movement practices, such as morning yoga or somatic grounding spaces at modern festivals, is so vital; they act as necessary energetic anchors, pulling overstimulated minds back down into the reality of the body. Implementing this requires a level of deliberate, forward-looking planning that can initially feel counter-intuitive to the wild, spontaneous ethos of a festival field. Yet this is the central paradox: a loose, impulsive approach often leads to a restrictive, uncomfortable experience, whereas clear internal structure is what grants you the freedom to explore safely.

A note on the whole picture

Reading back through this list, a pattern emerges that is worth naming explicitly. The substances that tend to serve the festival environment best share certain qualities: they amplify the collective rather than contracting attention inward; their duration is manageable within the rhythm of the day; they carry risks that are real but navigable with basic knowledge; and they do not demand redosing in ways that hijack the experience entirely. The substances that tend to undermine it share the opposite qualities: they work against the body’s need for recovery, they isolate rather than connect, and they create a pharmacological-driven state that pulls harder than the music does.

None of this is a prescription. People are different, contexts are different, and the same substance can serve one person well and another badly on the same afternoon in the same field. What true harm reduction asks - and what this piece has tried to model - is not abstinence or total freedom, but attention: to dose, to timing, to the environment, to the people around you, and to the difference between a choice made from curiosity and one made from social pressure or the momentum of a night already going sideways.

This is also not a definitive guide - and it should not be read as one. The pharmacology of psychoactive substances is a field in active development. Our understanding of drug interactions, individual neurobiological variation, long-term effects and harm reduction best practice continues to evolve. What is written here reflects the best available evidence and field experience at the time of publication, and future versions of this piece will be updated as that knowledge develops. If something here turns out to be incomplete or superseded, that is not a failure of the project - it is how honest interpretation of science and culture works.

The festival, at its best, is one of the more remarkable things human beings do together. It is loud and sweaty, commonly meaningful and occasionally absurd, and it touches something genuinely ancient - the need to gather, to move in time with others, to briefly suspend the ordinary self and return to something more collective. That experience does not require pharmacological assistance. But for those who choose to bring chemistry into it, the difference between a weekend that expands you and one that depletes you is usually not the substance itself. It is the knowledge brought to it.

The next part of The Map and the Weather series will be published in the next couple of weeks. Having mapped the high-stimulation of the crowd, the weather is about to shift. We will step away from the loud frequencies of the festival field and move into its quiet counterpart: the calm, solitary terrain of a walk in nature - exploring how silence and the woods alter the trajectory of a molecule. To get it directly in your inbox, make sure you are subscribed.

Subscribe now

Further readings

On collective effervescence and the sociology of gatherings Collins, R. (2004). Interaction Ritual Chains. Princeton University Press. - Collins builds Durkheim’s collective effervescence into a full theory of emotional energy. His framework explains not just why festivals work when they work, but why they sometimes don’t.

On the anthropology of ritual and communitas Turner, V. (1969). The Ritual Process: Structure and Anti-Structure. Aldine Publishing. - Where Durkheim describes the energy of collective gathering, Turner describes what happens to the self inside it: the suspension of ordinary roles, the brief equality of the threshold, the return transformed.

On carnival, festivity, and social inversion Bakhtin, M. (1984). Rabelais and His World. Indiana University Press. (trans. Hélène Iswolsky) - The foundational text for understanding the Feast of Fools, Saturnalia, and every gathering that has used festivity as a temporary escape from official culture. Bakhtin’s carnivalesque runs as an unbroken thread from medieval carnival to the modern festival field.

On the politics and sociology of the rave and free party movement Rietveld, H.C. (1998). This Is Our House: House Music, Cultural Spaces and Technologies. Ashgate. - A rigorous sociological account of house music culture as a spatial and political practice. Particularly useful for understanding why the environment of a rave is never merely a backdrop to the experience.

On festival culture, identity, and the temporary autonomous zone Bey, H. (1991). T.A.Z.: The Temporary Autonomous Zone, Ontological Anarchy, Poetic Terrorism. Autonomedia. - Bey’s concept of the Temporary Autonomous Zone - a gathering outside the structures of state and commerce, intense precisely because it is brief - has been quietly foundational to transformational festival culture for three decades.

On the sociology of contemporary music festivals Anderton, C., Dubber, A. & James, M. (2013). Understanding the Music Industries. SAGE Publications. (Chapter 9: Festivals and Live Music) - A grounded account of how the modern music festival operates simultaneously as an industry, a community, and a cultural form. Useful for thinking clearly about what is actually at stake in the difference between a commercial megafestival and a community-organised gathering.

On harm reduction at festivals Adley, M., Jones, G. & Measham, F. (2022). Drug Checking as a Harm Reduction Tool.Routledge. - A rigorous current account of festival harm reduction practice, including the work of organisations like The Loop. The most practically grounded entry on this list.

On MDMA and rave culture Collin, M. (1997). Altered State: The Story of Ecstasy Culture and Acid House. Serpent’s Tail. - The definitive cultural history of MDMA and the rave movement. Readable, well-researched, and honest about both the euphoria and the wreckage.

On user literature and experiential reporting Erowid. Erowid.org: Documenting the Complex Relationship Between Humans and Psychoactives. - The largest archive of first-person accounts of psychoactive substance use on the internet. Not peer-reviewed and not without bias, but an irreplaceable record of lived experience that formal pharmacology rarely captures. Best read critically and comparatively rather than as a source of dosing instructions.

References

[1] von Scheve, C. (2020). Collective emotions in rituals: Elicitation, transmission and a “Matthew-effect.” Emotions in Rituals and Performances, 55–77.

[2] Pizarro, J. J., Zumeta, L. N., Bouchat, P., et al. (2022). Emotional processes, collective behavior, and social movements: A meta-analytic review of collective effervescence outcomes during collective gatherings and demonstrations. Frontiers in Psychology, 13.

[3] Weir, A. (2017). Collective love as public freedom: Dancing resistance. Ehrenreich, Arendt, Kristeva, and Idle No More. Hypatia, 32(1), 19–34.

[4] Harris, M. (2011). Sacred Folly. Cornell University Press.

[5] Zinberg, N.E. (1984). Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. Yale University Press. ISBN 0-300-03110-6. 1 2

[6] Maughan, R.J. & Griffin, J. (2003). Caffeine ingestion and fluid balance: a review. Journal of Human Nutrition and Dietetics, 16(6), 411–420. https://doi.org/10.1046/j.1365-277X.2003.00477.x

[7] Smit, H.J. & Rogers, P.J. (2000). Effects of low doses of caffeine and carbohydrate on cognitive performance, mood and thirst in low and higher caffeine consumers. Psychopharmacology, 152(2), 167–179. https://doi.org/10.1007/s002130000506

[8] Collin, M. (1997). Altered State: The Story of Ecstasy Culture and Acid House. Serpent’s Tail.

[9] Neher, A. (1962). A physiological explanation of unusual behavior in ceremonies involving drums. Human Biology, 34(2), 151–160.

[10] Becker, J. (2004). Deep Listeners: Music, Emotion and Trancing. Indiana University Press.

[11] Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022). Therapeutic setting as an essential component of psychedelic research methodology. Frontiers in Psychiatry, 13, 965641. https://doi.org/10.3389/fpsyt.2022.965641 3

[12] Golden, T.L. et al. (2022). Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature. Current Topics in Behavioral Neurosciences, 56, 35–70. https://doi.org/10.1007/7854_2021_2984

[13] Pronovost-Morgan, C., Greenway, K.T., Roseman, L. et al. (2025). An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine, 31, 2186–2195. https://doi.org/10.1038/s41591-025-03685-9 5

[14] Brunt, T. (2021). Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. Neurotoxicity Research. https://doi.org/10.1007/S12640-021-00416-Z 6

[15] European Union Drugs Agency (EUDA) / EMCDDA (2022). Recreational settings and drugs: health and social responses. https://www.euda.europa.eu/publications/mini-guides/recreational-settings-and-drugs-health-and-social-responses_en 7

[16] Advisory Council on the Misuse of Drugs (ACMD) (2026). Ketamine: an updated review of use and harms. UK Government. https://www.gov.uk/government/publications/ketamine-an-updated-review-of-use-and-harms

[17] Georgieva, E. et al. (2021). Oxidative Stress and Cocaine Intoxication as Start Points in the Pathology of Cocaine-Induced Cardiotoxicity. Toxics, 9(12), 317. https://doi.org/10.3390/toxics9120317 9

[18] Dutton, C., North, E., Chun Tie, Y., Oliva, J. & Skeffington, P. (2025). Harm reduction practises for users of psychedelic drugs: a scoping review. Harm Reduction Journal, 22, 158. https://doi.org/10.1186/s12954-025-01264-2 1

[19] Pratschke, J. (2025). Harm reduction strategies for cannabis-related problems: a literature review and typology. European Archives of Psychiatry and Clinical Neuroscience, 275, 379–388. https://doi.org/10.1007/s00406-024-01839-34

[20] Masento, N.A., Golightly, M., Field, D.T., Butler, L.T. & van Reekum, C.M. (2014). Effects of hydration status on cognitive performance and mood. British Journal of Nutrition, 111(10), 1841–1852. https://doi.org/10.1017/S0007114513004455 5

[21] Smit, H.J. (2011). Theobromine and the pharmacology of cocoa. Handbook of Experimental Pharmacology, 200, 201–234. https://doi.org/10.1007/978-3-642-13443-2_7

[22] Caudevilla-Gálligo, F., Riba, J., Ventura, M. et al. (2012). 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology, 26(7), 1026–1035. https://doi.org/10.1177/0269881111431752

The Map and the Weather

The map gives you the terrain. But anyone who has ever walked in forests or in the mountains knows that the same landscape feels entirely different depending on the weather. A mountain path that is a gentle afternoon walk in sunshine becomes a serious undertaking in fog and wind. Or at night. The terrain hasn’t changed, but the conditions have changed everything.

Psychoactive substances work the same way. The map - stimulants (or ‘uppers’), depressants (or ‘downers’), psychedelics (or ‘openers’) - describes the territory. The mental landscape, if you will. But set and setting are the weather. And just as an experienced mountaineer chooses their route based on both the terrain and the forecast, a wise navigator of altered states considers their substance - from coffee to cacti - in light of both its pharmacological profile and the conditions they are entering.

Some substances are clear-skies tools - remarkable in the right conditions, genuinely dangerous in the wrong ones (hello, LSD). Others are more forgiving across a range of contexts (enter MDMA). And some combinations of substance and setting are so mismatched that no amount of experience or intention can compensate (think cocaine in a forest or mushrooms in a shopping mall).

The container - the context, the intention, the setting - is not incidental to the pharmacological experience. In many cases, it is virtually inseparable from the pharmacology itself.

From Jazz Clubs to Harvard: The Origins of Set & Setting

In Western society, the argument that context shapes drug experience began, quietly and rigorously, in the jazz clubs of 1940s Chicago.

In 1953, the sociologist Howard Becker - himself a jazz pianist who had spent years embedded in the Chicago music scene - published a paper that would become one of the most cited studies in the sociology of drug use. [10] Becoming a Marihuana User documented something that the prevailing medical/pharmacological model could not explain: why some people got high the first time they used cannabis and others did not, despite taking the same substance in the same dose. The answer, Becker found, had almost nothing to do with molecules and receptors - it had everything to do with the social context.

Through fifty interviews with cannabis users, Becker identified a three-stage process that almost all of them had gone through. First, learning the technique - how to inhale properly, how to hold the smoke, how to actually get the drug into the system in a way that produced effects. Second, learning to perceive the effects - recognising the subtle changes in perception, time and sensation that cannabis produces, which are easy to miss or misattribute without guidance from more experienced users. Third, and most remarkably, learning to enjoy the effects - discovering that the dizziness, the altered time perception, the heightened sensory awareness were pleasurable rather than alarming, a reframing that almost always happened through social interaction with people who already had that relationship with the substance. [10]

The implication was radical. Getting high on cannabis was not simply a pharmacological event: it was a learned social practice. The drug did not produce the experience on its own - the experience was co-produced by the substance, the social environment, the guidance of more experienced users, and the interpretive framework the user brought to it. Remove the social context and the same molecule produced confusion, anxiety or nothing at all.

Turn On, Tune In, Set Back by Decades

In the early 1960s, Timothy Leary and Richard Alpert were conducting psilocybin research at Harvard - some of the first systematic studies of psychedelic experience in a Western academic context. What they observed, repeatedly, was that the same dose of the same substance produced wildly different outcomes depending on who took it, in what state of mind, and in what environment. A session conducted in a calm, supportive setting with clear intention produced experiences that participants described as among the most meaningful of their lives. The same dose in a cold, clinical and hypermedicalized context produced something closer to a nightmare. [8]

Leary named this observation set and setting - set referring to the mindset, expectations and emotional state of the person; setting referring to the physical and social environment. It was a genuinely revolutionary insight. For the first time in the psychedelic context, the question shifted from “what does this drug do?” to “what does this drug do, to this person, in this context?” - a reframing that should have transformed drug research and education.

What happened instead is well documented. Leary, brilliant and reckless in roughly equal measure, abandoned the careful research framework that might have embedded the set and setting insight into mainstream medicine and chose instead the role of countercultural prophet. “Turn on, tune in, drop out” - his 1967 rallying cry - was designed to provoke, and it succeeded. Richard Nixon called him “the most dangerous man in America.” The political establishment, already alarmed by the anti-Vietnam War movement with which psychedelics had become associated, used Leary’s showmanship as justification for a total crackdown - one that quickly went global, shutting down decades of promising research almost overnight. [9]

It would be too simple to lay the prohibition at Leary’s feet alone. In the 1960s there was genuinely very little understanding of how to use these substances safely - no dosing guidelines, no harm reduction infrastructure, no cultural framework for preparation. The average LSD blotter is estimated to have contained 300 to 400 micrograms - a dose that would make most contemporary harm reduction practitioners go pale. Accidents happened, some serious, and a media already primed to frame psychedelics as a threat amplified them into a moral panic. The prohibition that followed was disproportionate and politically motivated - but it fed on real incidents and a genuine absence of the harm reduction knowledge that might have prevented them.

The irony remains considerable. The man who most clearly articulated the principle that context determines outcome contributed significantly to creating the conditions in which that principle could not be studied, taught or applied for the next forty years. The insight survived. The research did not.

Norman Zinberg and Self-Regulation

It was left to Norman Zinberg, a psychiatrist at Harvard Medical School, to rescue the set and setting framework from the wreckage. Where Leary had been a provocateur, Zinberg was a careful empiricist. His 1984 book Drug, Set, and Setting documented something that the dominant narrative of addiction said was impossible: sustained, non-destructive drug use. Studying people who used heroin, cannabis and psychedelics recreationally without becoming dependent, Zinberg asked why - and found that the answer lay not primarily in the pharmacology of the substances their were using but in the social rituals and rules surrounding them. [1] Biology and individual vulnerability still mattered - Zinberg was clear that a non-destructive relationship is considerably harder to maintain with highly addictive opioids than with cannabis or psychedelics - but even accounting for those differences, the contextual factors were doing most of the protective work.

It was a finding with radical implications for drug policy that mainstream medicine took another forty years to begin absorbing. Part of the reason is structural and worth naming honestly. Most doctors encounter psychoactive substances through a heavily filtered lens: the emergency room patient in crisis, the person presenting with dependence, the acute psychiatric admission. These are real and important encounters - but they represent a systematically skewed sample. The people who navigate these substances carefully and without harm have no reason to mention it to their doctor, and most wouldn’t. The result is that many clinicians develop a genuine and sincerely held belief that psychoactive substances are predominantly dangerous - not because they are dishonest, but because the population they see is not representative. They are, in Zinberg’s terms, seeing the set and setting failures and almost never the successes. It is a bias built into the structure of medical practice itself - and it goes a long way toward explaining why the advice most patients still receive today, if they receive any at all, amounts to little more than “you should not take drugs, they are bad for your health.” - a sentence that has never once changed anyone’s behaviour, but has ended many conversations. Zinberg’s work suggested something more useful was possible. This series is an attempt to build on it - with one significant advantage he did not have: a neuroscience that can now begin to explain why.

The Neuroscience Catches Up

Every psychoactive experience is the product of a three-way interaction: the pharmacology of the substance, the internal state of the person taking it - their expectations, their emotional history, their filters and bias - and the external environment in which it is taken. Change any one of these variables and you change the experience. Change two of them and you may be describing what feels like an entirely different substance. [1, 2]

The predictive processing framework, which is arguably the most influential theory in 21st century neuroscience, helps explain why. The brain does not passively receive sensory information from the world - it constantly generates predictions (also known as ‘priors’, ‘models’ or ‘beliefs’) about what it expects to experience, using accumulated knowledge and memory to build models of reality before the sensory data even arrives. It then uses incoming information primarily to correct errors in those predictions - updating its models when reality diverges from expectation. [4, 5]

As the neuroscientist Anil Seth puts it: “We’re all hallucinating all the time; when we agree about our hallucinations, we call it reality.”. Consider what happens when you walk into a crowded room and spot someone you think you recognise. Before you have consciously processed their features, your brain has already generated a prediction - a face, a name, a set of associations. If the person turns out to be a stranger, the gap between prediction and reality produces a brief but unmistakable jolt of disorientation as the brain updates its model. You were not passively seeing the environment - were actively predicting the world around you, and using what you saw to correct the prediction.

Drugs interact with this system in ways that go far beyond simple chemistry. Consider someone returning home after six months away. They walk into their kitchen and notice things they had long since stopped seeing - the particular quality of the light, the smell, the arrangement of objects on the counter. Their model of that kitchen had become so automatic, so deeply grooved by repetition, that the actual sensory data was being filtered out almost entirely. Absence has weakened the prior, and suddenly the bottom-up signal floods through. This is, in miniature, what psychedelics do to the entire perceptual system - not by adding something new, but by loosening the top-down predictions that normally filter experience into the familiar. The world does not change. The filter does. [5]

This loosening is profoundly shaped by context. A substance taken in a state of anxiety, in an unfamiliar environment, with no preparation, is being processed by a brain whose predictive models are already running in threat-detection mode - and the loosening of those models produces something very different from the same substance taken in a state of calm, in a trusted setting, with clear intention. The pharmacology is identical. The predictive context is not. [4, 5]

In my time providing acute crisis care at festivals, the presentations that stay with you are not always the ones involving the most extreme pharmacology - though there is plenty of that: very high doses of LSD, combinations of multiple substances, pills of unknown content taken in unknown quantities. What is striking is how often the determining factor in whether someone navigates a difficult experience or is overwhelmed by it is not the substance itself, but the conditions surrounding it - the preparation, the presence of trusted people who know how to support you, the unexpected events, the capacity to deal with uncertainty, the environment. The weather, in other words, matters even when the terrain is genuinely extreme.

A Note on Vulnerability

It is worth pausing on an implication of the set and setting argument that the psychedelic hype machine has a tendency to brush past. The heightened sensitivity to context that psychedelics produce is most acute during the experience itself - when the ordinary filters of perception and self-protection are loosened and the brain is unusually open to whatever the environment, the people present, and the framing of the experience are offering. It is in this window of acute altered consciousness that the double edge of that sensitivity becomes most visible.

In clinical settings, this heightened openness to the context is one of several factors that researchers believe underlies therapeutic outcomes - alongside the quality of the therapeutic relationship between therapist and the patient. [11] But the same responsiveness that allows a skilled therapist to help a patient approach difficult material also made psychedelics valuable to the CIA for interrogation and brainwashing experiments in the 1950s, and allowed figures like Charles Manson to use them as tools of psychological control. [12, 13] These are not historical footnotes. As long as there are manipulative people looking to exploit the vulnerable, the psychedelic space will be shadowed by unscrupulous practitioners - and the current renaissance, with its combination of cultural enthusiasm and regulatory gaps, has created conditions in which caution and discernment matter more than ever.

Awareness of this dynamic should not be a reason to avoid psychedelics. It is a reason to be careful about who holds the container - and to be sceptical of anyone who claims that their particular container is beyond question. This is precisely what harm reduction education exists to do: to ensure that people entering altered states have the information, the support and the agency to navigate them on their own terms.

Beyond the Molecule: Context Without Substances

If the set and setting argument is taken seriously - if context is genuinely as important as the compound - then it leads to a conclusion that is rarely stated explicitly in Western scientific literature, though it has been understood for millennia in traditions that never needed a laboratory to demonstrate it: altered states of consciousness do not require substances at all. The molecule is one route into the territory. It is not the only one - and for most of human history, it was not even the primary one.

Yogic and Vedic traditions developed pranayama - systematic breath control as a path to altered states - thousands of years before the word psychedelic existed. Sufi traditions cultivated ecstatic states through dhikr, rhythmic chanting and movement. Indigenous cultures across every continent developed drumming, fasting, sweat lodges, vision quests and ritual dance as technologies for accessing non-ordinary consciousness - practices whose neurobiological effects we are only now beginning to map with the tools of 21st century neuroscience. Buddhist meditation traditions documented the phenomenology of altered states with a precision that modern psychology is still catching up with [17]. These were not primitive approximations of something that Western science would later do properly. They are sophisticated systems, empirically refined over generations, with their own understanding of set and setting — and their own accumulated wisdom about which practices serve which intentions.

The most direct Western demonstration of this principle came from the psychiatrist Stanislav Grof. After LSD and psilocybin were effectively banned from research in the late 1960s, Grof - who had spent years practising LSD-assisted therapy - faced a practical problem: how to continuing that exploration without the substances that had opened it. [14] The answer he and his wife Christina developed at the Esalen Institute in California in the mid-1970s was holotropic breathwork: drawing on pranayama, shamanic traditions of rhythmic breathing and his own psychedelic research, they developed a method combining accelerated breathing, evocative music and a carefully structured setting to induce states that Grof described as functionally similar to those produced by psychedelics. [14] Grof was not inventing something new - he was translating something ancient into a form that a post-prohibition Western research context could work with.

Holotropic breathwork is the most formally developed example of a much broader phenomenon. Flow states - the absorption that comes with making music, running long distances, dancing, religious chanting, collective sport, deep meditation - produce measurable changes in brain activity that share features with psychedelic states: suppression of the default mode network, reduced self-referential processing, heightened sensory awareness, a loosening of the ordinary boundaries of the self. [15] The brain does not particularly care whether its predictive filters are being loosened by psilocybin or by three hours of drumming in a sweat lodge: the initial mechanism differs, but the destination overlaps.

This has a practical implication that harm reduction literature rarely addresses directly, but which is arguably one of the most important principles in the field. If psychoactive substances are the only tool someone uses to access relaxation, stimulation or creativity - if cannabis is the only route to relaxing, or MDMA the only route to emotional openness, or alcohol the only route to social ease - then the risk of dependency increases substantially, regardless of the pharmacological profile of the substance. The brain learns what works, and it returns to it. A regular practice of non-pharmacological altered states - movement, meditation, breathwork, music, time in nature - is not just a wellbeing recommendation. It is a harm reduction principle. It builds the capacity to access the same territory through multiple routes, which means no single route becomes indispensable.

The relationship between contemplative practice and psychedelic experience is also synergistic rather than merely parallel. Growing evidence suggests that mindfulness meditation and psychedelics share overlapping neurobiological mechanisms and that the benefits of each are enhanced when both are present. [16] Meditation appears to deepen and stabilise the insights that psychedelic experiences can catalyse; psychedelics, in turn, can open the door to meditative states that years of practice might not otherwise reach. [16]

Context is more signal than noise. What follows is an attempt to act on that.

What This Series Will Cover

What will follow is a rough guide to five specific contexts, each one a different kind of weather for the same underlying terrain.

The music festival. High stimulation, large crowds, heat, sleep deprivation, strangers becoming friends. The context that gave birth to modern harm reduction practice - and the one where the gap between what people know and what they need to know is most consequential.

A walk in nature. Low stimulation, open sky, physical movement, solitude or a small trusted group. Perhaps the oldest context for psychedelic use in human history - and one that the harm reduction literature has only recently begun to map properly.

An intimate evening at home with a romantic partner. Private, emotionally safe, no obligations. One of the most frequently described substance-context fits in user literature - and one of the least discussed outside of it.

Creative work. Mental focus or expansiveness, a project or question to work with, low social pressure. The context with the longest cultural history of substance use - and the one where the mythology has most dramatically outrun the evidence.

A celebration at home with friends. Familiar environment, trusted group, shared history, laughter, music, food. A very common real-world context for psychoactive substances - and one that drug education is commonly silent about.

Each post will cover the substances most relevant to that context: what the harm reduction literature says, what users consistently report, and what the evidence suggests about which combinations of substance and setting tend to serve people well - and which tend not to. The tone is honest rather than cautionary, evidence-based rather than moralistic.

Nothing in this series constitutes medical advice or encouragement to use controlled substances.

The principle that runs through all five posts is the same. The terrain changes. The weather changes. The map is the same map.

References

[1] Zinberg, N.E. (1984). Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. Yale University Press.

[2] Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022). Therapeutic setting as an essential component of psychedelic research methodology. Frontiers in Psychiatry, 13, 965641. https://doi.org/10.3389/fpsyt.2022.965641

[3] Golden, T.L. et al. (2022). Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature. Current Topics in Behavioral Neurosciences, 56, 35–70. https://doi.org/10.1007/7854_2021_298

[4] Friston, K. (2010). The free-energy principle: a unified brain theory? Nature Reviews Neuroscience, 11(2), 127–138. https://doi.org/10.1038/nrn2787

[5] Carhart-Harris, R.L. & Friston, K.J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160

[6] Pronovost-Morgan, C., Greenway, K.T., Roseman, L. et al. (2025). An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine, 31, 2186–2195. https://doi.org/10.1038/s41591-025-03685-9

[7] Mithoefer, M.C., Mithoefer, A.T., Feduccia, A.A. et al. (2018). MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486–497. https://doi.org/10.1016/S2215-0366(18)30135-4

[8] Leary, T., Litwin, G.H. & Metzner, R. (1963). Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease, 137(6), 561–573.

[9] Greenfield, R. (2006). Timothy Leary: A Biography. Harcourt.

[10] Becker, H.S. (1953). Becoming a marihuana user. American Journal of Sociology, 59(3), 235–242. https://doi.org/10.1086/221326

[11] Carhart-Harris, R.L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I. and Kaelen, M., 2018. Psychedelics and the essential importance of context. Journal of psychopharmacology, 32(7), pp.725-731.

[12] Lee, M.A. & Shlain, B. (1985). Acid Dreams: The Complete Social History of LSD. Grove Press.

[13] O’Neill, T. (2019). Chaos: Charles Manson, the CIA, and the Secret History of the Sixties.

[14] Grof, S. & Grof, C. (2010). Holotropic Breathwork: A New Approach to Self-Exploration and Therapy. SUNY Press

[15] Millière, R., Carhart-Harris, R.L., Roseman, L., Trautwein, F.M. & Berkovich-Ohana, A. (2018). Psychedelics, meditation, and self-consciousness. Frontiers in Psychology, 9, 1475. https://doi.org/10.3389/fpsyg.2018.01475

[16] Smigielski, L., Kometer, M., Scheidegger, M. et al. (2019). Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports, 9, 14914. https://doi.org/10.1038/s41598-019-50612-3 5

[17] Batchelor, S. (1997). Buddhism without beliefs: A contemporary guide to awakening. Riverhead Books.

Further Reading

On set, setting and the pharmacology of context Zinberg, N.E. (1984). Drug, Set, and Setting: The Basis for Controlled Intoxicant Use. Yale University Press. - The foundational text. Zinberg’s argument - that set and setting are as important as the substance itself — was radical in 1984 and remains underabsorbed by mainstream drug education forty years later. The rigorous empirical rescue of an insight that Timothy Leary named but could not protect.

On the sociology of drug use and context Becker, H.S. (1953). Becoming a marihuana user. American Journal of Sociology, 59(3), 235–242. - A short, readable and remarkably prescient paper. Becker documented the importance of social context in shaping drug experience a decade before the term set and setting existed - and did it through careful empirical observation rather than theory.

On Timothy Leary and the history of psychedelic research Greenfield, R. (2006). Timothy Leary: A Biography. Harcourt. - The most comprehensive account of Leary’s life and legacy - the genuine intellectual contribution, the recklessness, and the political consequences. Essential for understanding why the set and setting insight took forty years to re-enter mainstream science.

On the original set and setting research Leary, T., Metzner, R. & Alpert, R. (1964). The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead. University Books. - Leary’s own attempt to operationalise the set and setting framework as a practical guide. Historically important, occasionally eccentric, and a direct window into both the insight and the recklessness that defined his contribution.

On the neuroscience of psychedelics and context Carhart-Harris, R.L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I. and Kaelen, M., 2018. Psychedelics and the essential importance of context. Journal of psychopharmacology, 32(7), pp.725-731. - The neuroscientific case for set and setting in contemporary psychedelic science. Readable for a non-specialist audience and directly relevant to everything this series argues. The title says it all.

On the science of consciousness Seth, A. (2021). Being You: A New Science of Consciousness. Dutton. - The most accessible current account of predictive processing and the constructed nature of conscious experience. Provides the neuroscientific framework that underlies much of what this series describes. No prior science knowledge required.

You’ve probably already noticed that the conversation about drugs has changed dramatically in recent years. First of all, the language itself is changing: instead of saying “drugs,” many people are saying “psychoactive substances” or even “medicines.” Magic mushrooms are on the cover of serious magazines, and everyone’s calling it psilocybin instead. Your most sensible friend has started microdosing something. What everyone used to know as Ecstasy is now being called MDMA, and it’s being studied to treat mental health conditions. Your yoga teacher may or may not have mentioned ayahuasca. Someone you know was prescribed ketamine therapy and told you it saved them from depression - and someone else you also know started using ketamine to have fun and now they’re struggling to stop it. There is more information available than ever before - newspaper articles, wellness influencers, peer-reviewed papers, retreat testimonials and youtube rabbit holes - often on the same substance, rarely in agreement. Also rare is trustworthy guidance to make sense of it all - something based on evidence and real-world experience. A map for navigating the landscape itself, and the intentions around the journey. That’s what I’m trying to build here: a place for the curious who want to be careful, and for the careful who are getting curious.

I am a psychiatrist who has spent fifteen years studying psychoactive substances in hospitals and research labs, twenty years attending festivals and clubs where they are part of the culture, and the last five providing frontline crisis care at Boom Festival in Portugal - one of Europe’s largest psychedelic gatherings. I have my own blind spots and some strong opinions, and I certainly don’t have all the answers. That combination of perspectives is what this Substack is built on.

Every society is a high society.

Cultural historian Mike Jay has spent decades documenting the rarely discussed fact that every human culture in recorded history - without exception - has used psychoactive substances [1]. Coffee, coca leaf, cannabis, wine, peyote, tea, ayahuasca, opium. The desire to alter one’s state of mind is one of the most ancient and universal expressions of being human - not a modern pathology, a moral failure, or a sign of weakness.

So why does it feel so dangerous to talk about it openly and honestly?

The Word Was Weaponised

In Western society, the word “drug” - as we use it today, meaning dangerous, illegal, addictive - did not exist until the 20th century.

In the 19th century, “drug” simply meant anything you could buy in a pharmacy. Laudanum (opium dissolved in alcohol) was sold freely on every high street, taken by factory workers, poets and Victorian housewives alike. Cannabis was also exploding in popularity; in the 1840s, it was used in enormous oral doses by Parisian artists and writers like Balzac, Victor Hugo and Baudelaire, who described experiences strikingly similar to a modern psychedelic journey. Rather than a passing trend, it evolved into a definitive mainstay of late nineteenth-century medicine. Doctors frequently relied on it as a successful intervention for chronic pain and various ailments, prescribing it to standard patients and prominent figures, including Queen Victoria.

Then, at the turn to the 20th century, the playbook of criminalization began in the United States. Opium was suddenly reframed as a dangerous “Chinese” substance. The historical amnesia across the Atlantic was staggering: only a few decades earlier, the UK had weaponized the opium trade, flooding China with the drug to secure Western economic and colonial power. But American domestic politics required a new scapegoat. Despite Western women buying laudanum over the counter for decades, the moment Chinese immigrant workers became economically inconvenient after building the US railroads, their drug of choice was deemed a threat to civilization. The substance had not changed - but the politics had.

A few decades later, the US government used the exact same tactic on a new target. Certain substances were criminalised - not because of science, but because of power, race, and authority. The US government started referring to cannabis as “marijuana” to explicitly tie it to Mexican immigrants. Cannabis had been used in American medicine for decades. But rename it, associate it with the very foreigners you want to blame for your economic failures, and suddenly it becomes a terrifying threat.

To be sure, these laws weren’t born in a vacuum; genuine, if often misguided, public health concerns and international treaty pressures also drove early drug legislation. But these factors were not incidental to the racial politics - they were deeply intertwined with them. LSD and psilocybin were banned in the late 1960s not because they were shown by science to be unsafe, but because they were being used by people who opposed the Vietnam War.

And while political panic sparked these laws, commercial interests are what cemented them. For decades, the immense lobbying power of the alcohol industry has been quietly deployed to fight the regulation of competing substances, protecting market share under the guise of public safety.

The language of danger was constructed deliberately, and it stuck. The result? A century of drug policy built not on racism, power and fear - instead of evidence.

What the Science Actually Says

In 2010, Professor David Nutt and colleagues published a landmark study in The Lancet - one of the world’s most respected medical journals - ranking 20 of the most common psychoactive drugs by actual harm, to the user and to others [2].

The results were striking (Figure 1).

Alcohol ranked as the single most harmful drug overall - more harmful than heroin, crack cocaine, or methamphetamine. Psilocybin mushrooms and LSD ranked as the least harmful of the substances assessed. MDMA and cannabis ranked significantly below both alcohol and tobacco. [2]

This is peer-reviewed, published, mainstream research. And yet alcohol and tobacco are legal, marketed and sold on every corner, while psilocybin and MDMA are Schedule 1 in most countries - classified as having “no medical value” - despite scientific studies showing they can be used to treat depression and PTSD, when paired with psychological support.

The rankings depend partly on how you weight harms to self versus harms to others - and that weighting is contested. But even adjusting for different methodological choices, the basic picture holds: alcohol and tobacco consistently rank among the most harmful substances assessed.

The legal frameworks we have inherited create a false binary: legal equals safe, illegal equals dangerous. But the actual harm spectrum does not work that way. Caffeine sits at the safe end. Alcohol and tobacco sit at the harmful end. Everything in between - including substances considerably safer than alcohol and tobacco - was rendered invisible for years by a legal classification system that was never designed to inform. And it is in that invisible middle ground that some interesting territory lies.

The conclusion is simple: current drug laws are not a reliable guide to the safety of drugs. Science can be.

The Hidden Hands: Science, Festivals, and the Keepers of the Flame

It is worth pausing to acknowledge those who kept the knowledge alive, and those who helped make the science possible.

Amanda Feilding, founder of the Beckley Foundation, has been called the ‘hidden hand’ behind the resurgence of psychedelic science. She initiated and funded some of the world’s first brain imaging studies of LSD and psilocybin, co-authored over 80 peer-reviewed papers, and was among the first to build a rigorous scientific evidence base for drug policy reform [3]. She passed away in May 2025, leaving behind a legacy that has quietly reshaped the entire field.

It is also worth acknowledging that from the 1970s through to the late 2000s, when psychedelic research was effectively shut out of mainstream science, festival and gathering culture preserved the lived knowledge of these substances. The harm reduction organisations that now operate at festivals - Kosmicare, The Loop, Zendo Project - are the inheritors of that accumulated field wisdom.

The Map We Were Not Given at School

Most of us grew up with one of two frameworks for thinking about drugs: “just say no” or “just don’t get caught.” Neither is particularly useful.

What everyone needs, and was never given at school, is a map that can help make informed decisions. And it turns out, pretty good ones exist.

The desire to classify the substances humans use to alter their minds is itself as old as the practice. The Greek physician Dioscorides, writing in the first century AD, documented over a thousand medicinal substances in his encyclopaedic De Materia Medica - including cannabis, opium and mandrake - laying the foundations for pharmacology as a discipline.

In 1924, the German pharmacologist Louis Lewin published Phantastica, the first systematic attempt to organise psychoactive substances by their effects on the human mind. His five categories have a poetry that modern pharmacology has never quite matched: Euphorica (the narcotics and opiates); Phantastica (the hallucinogens or psychedelics); Inebriantia (the inebriants - alcohol and ether); Hypnotica (the tranquillisers); and Excitantia (the stimulants). A century later, a framework used by harm reduction researchers - and the one I will use here - simplifies and updates Lewin’s vision into three overlapping classes: stimulants (or ‘uppers’), depressants (or ‘downers’) and psychedelics (which some like to call ‘openers’).

The figure below is the Drugs Venn, developed by the harm-reduction researchers Mark Adley, Guy Jones and Professor Fiona Measham, published in the peer-reviewed journal Drugs: Education, Prevention and Policy (2022) [6]. It deliberately uses three overlapping categories to reflect how many substances sit somewhere between classes rather than neatly within one.

A map like this is more than an academic exercise. It is an invitation to ask a question that most people never think to ask before reaching for a substance: what is my actual intention? Am I seeking relaxation or a chance to wind down - the territory of ‘downers’ or depressants? A boost of energy, deeper connection or celebration - the territory of stimulants and empathogens? Creative or inner expansion - the territory of psychedelics? Knowing which territory you are entering, and why, is one of the most important harm reduction practices there is.

But it leads directly to the next crucial question: Am I in the right place - internally and externally - to enter it? A classification of substances without a classification of contexts is only half the picture, and arguably the less important half. The most consistent finding in contemporary psychedelic research is that set and setting are not peripheral variables. They are primary determinants of outcome. The same dose of psilocybin that produces a therapeutically transformative experience in a supported setting can produce a destabilising one in a chaotic or unsupported environment. Context is not incidental to the pharmacology. In many cases, it is the pharmacology. A future post will explore exactly this.

One final note before we enter the map. For some people, at certain moments in their lives, using psychoactive substances carries far more risk than potential benefit. If you are navigating a mental health condition, or if you have a first-degree relative with schizophrenia or another psychotic disorder, that decision should never be made alone - it requires the input of a qualified professional who is genuinely informed on the topic.

A Brief Tour of the Territory

The detailed guides to each substance class - their pharmacology, their harm profiles, their optimal contexts, and the harm reduction principles that apply to each - will be the subject of dedicated posts in this series. But here is the shape of the terrain.

Stimulants accelerate the central nervous system, often by increasing the availability of dopamine, serotonin, and norepinephrine - the neurotransmitters of motivation, reward, and alertness. What goes up, however, must come down - and how far down depends enormously on what you took, how much, and how often.

Caffeine is the world’s most used and safest psychoactive substance - so embedded in daily life that most people don’t think of their morning coffee as a drug at all. It is highly addictive, but extremely safe: a distinction that will feel academic the morning you decide to quit and find yourself unable to form a sentence before noon. Unlike heavier stimulants, it works primarily by blocking the brain’s “tiredness” chemicals, providing a clean boost to focus, sustained attention, and mood without drastically altering your perception.

Cocaine is typically sought out for its immediate payoff: a rapid surge of confidence, a sharp drop in social anxiety, and a fleeting feeling of effortless focus and charm. It also has a particular tendency to make you feel sharper, more important, and more interesting than everyone else in the room. This may feel good to you; the people around you may not feel exactly the same way. Beyond the social illusion, it carries a remarkably poor harm-to-benefit ratio across the board - high addiction potential, serious cardiovascular risk, and a duration so short that compulsive re-dosing becomes almost inevitable.

Methamphetamine sits at the far end of the spectrum: massive dopamine and norepinephrine flooding, overwhelming physical energy and hyper-alertness, severe neurotoxicity, devastating long-term mental health consequences. There is no recreational use case that justifies the risk.

Depressants include alcohol - one of the most culturally normalised drugs - alongside benzodiazepines and opioids. What unites them is a quieting of anxiety (or sadness) that, at low doses, can feel like relief, and at higher doses dismantles the mind’s ability to self-monitor.

Most people drink alcohol because it facilitates social interactions. One of its main problems is that it not only reduces anxiety and creates moments of fun and laugher, but also increases impulsivity and diminishes decision-making capacity. Its unique association with interpersonal violence (including violence against women and sexual abuse), its role as the primary driver of nocturnal accidents, and its staggering societal costs - estimated at £18.5 billion per year in the UK alone - deserve far more honest public conversation than they receive. Instead, that conversation is routinely blocked by the alcohol industry’s massive political influence - arguably the chief obstacle to any real change.

Opioids like heroin occupy a different register entirely: their capacity to numb both physical and emotional pain makes them deeply appealing for someone who is suffering or carrying a history of trauma - and deeply dangerous for the same reason. Heroin rewires the brain’s reward system with terrifying speed, locking users into a brutal cycle of physical dependence where avoiding the agony of withdrawal becomes a full-time struggle for survival, constantly shadowed by the very real, immediate risk of fatal overdose.

Cannabis is a much less harmful ‘downer’ than alcohol and opioids, but as it sits across all classes, it is covered separately below.

Classic psychedelics - psilocybin, LSD, DMT/ayahuasca, mescaline - share an exceptionally low physiological toxicity profile and are among the least harmful substances in Nutt’s analysis. None are physically addictive. None have a known lethal dose from the substance itself. Their risks are primarily psychological - and significantly mitigated by the context in which they’re used (typically referred to as “set and setting”), including preparation and integration. It is worth being clear about what this means: the low harm profile of classic psychedelics applies to use in supported contexts. Difficult and destabilising experiences are not rare, and a small number of people experience lasting psychological difficulties.

What they offer, when those conditions are met, is genuinely remarkable. Classic psychedelics work by binding to serotonin 2A receptors, triggering a dramatic increase in brain activity diversity and complexity. Brain regions that don’t normally communicate begin talking to each other. The default mode network - the neural basis of our sense of self, our inner narrator, our ego - quiets or dissolves entirely.
The result is heavily dose-dependent - and, as we will explore, profoundly shaped by set and setting. At lower doses, changes in perception, emotional amplification, new perspectives and a quality of wonder that most adults haven’t felt since childhood; at higher doses, a dissolution of the boundaries between self and world - what researchers call ego dissolution - that can be terrifying, transcendent, or both, and that many people describe as among the most meaningful experiences of their lives. In the weeks following a single administration, there is growing evidence of increased neuroplasticity [7] - a temporary reopening of learning capacities and heightened psychological flexibility that researchers believe may underlie the lasting changes people report. It is this unique state that allows the mind to disrupt deep-rooted habits and break through entrenched patterns of thought or behaviour.

The mind is not broken under classic psychedelics. It is temporarily reorganised. And that reorganisation, held in a good container, is precisely where the healing potential lies - which can be a useful thing to remember at hour four of LSD, when it may not feel that way.

MDMA - aka ecstasy - sits between stimulants and psychedelics in the Drugs Venn. While it shares this hybrid territory with 2CB (another relatively safe compound), MDMA warrants a closer look. When used occasionally, at moderate doses, with proper testing and adequate spacing between uses, it has a remarkably good safety profile — scoring 9 out of 100 on Nutt’s harm scale, compared to alcohol’s 72. Contrary to popular belief, it carries a relatively low potential for addiction. It profoundly increases empathy (it is also known as an ‘empathogen’), emotional openness and interpersonal connection, and is widely used in festivals, clubs and raves. MDMA has a unique tolerance profile: because it relies on releasing the brain’s existing stores of serotonin, using it too frequently rapidly diminishes its empathogenic effects, offering lower returns while drastically increasing the comedown. Ultimately, it is a substance that rewards careful attention to dose and frequency - and punishes carelessness in ways that are well understood and largely avoidable.

Ketamine also deserves a note of its own, sitting as it does at the intersection of ‘downers’ and psychedelics. When inhaled as a powder - its most common recreational form - it typically produces relaxation and reduction of anxiety, alongside distinctive changes in bodily perception: a sense of separation from the body and the immediate surroundings that deepens with dose, and at higher doses can extend to a profound disconnection from the mind itself. It also has meaningful analgesic properties, which partly explains its longstanding use in medical settings (where it is mostly used in general anesthesia). In clinical settings, administered intravenously or intramuscularly at appropriate doses and schedules, with psychological support, it has genuine and growing evidence for treatment of depression [8]. Recreationally, however, the picture is very different: dissociation in uncontrolled settings carries significant risks, and the rise of ketamine use and dependency - particularly in the UK - is a matter of serious concern [9]. Ketamine causes three types of harm that are virtually absent from classic psychedelics: a significant risk of dependency; severe bladder damage with frequent use; and a risk of fatal overdose through respiratory depression, with associated deaths increasing in recent years [9,10]. If someone presents it as a safe tool for celebration or consciousness exploration, that framing deserves scrutiny.

And then there is cannabis - which resists classification almost as a matter of principle.

Cannabis has been used by humans for millennia and sits at the intersection of all three classes depending on strain, dose and context - the most versatile and most misunderstood psychoactive plant in human history. Most people who use it do so because it reduces anxiety while amplifying most sensory modalities (particularly to music and touch) and increasing creativity. It also has pain relief properties and, contrary to opioids and alcohol, there is no risk of overdose. It is the most widely used controlled substance in the world for a reason. The risk of dependence is present and moderate, but can be significantly reduced if used with knowledge, intention and discipline - terms rarely associated with cannabis use these days.

The THC:CBD ratio matters enormously: indica strains, higher in CBD, are commonly used for relaxation and anxiety reduction, while sativa strains, lower in CBD, are more stimulating and used as a social lubricant or for creative purposes. High-THC products can have psychedelic-like effects but carry a meaningfully increased risk of panic attacks and paranoia. Cannabis can trigger psychotic symptoms even in otherwise healthy individuals - and in those with a personal or family history of psychosis, the risk is significantly elevated [11]. Someone with a first-degree relative with schizophrenia or another psychotic disorder should approach cannabis, particularly high-THC products, with considerable caution - or avoid it altogether.

Importantly, the cannabis available today is not your parents’ cannabis - prohibition has produced a market dominated by very high-THC products, which makes using very small amounts more important than ever (and mixing it with CBD-only cannabis, instead of tobbaco). There is a certain irony in the fact that cannabis also contains CBD - a compound with well-documented antipsychotic properties, which has been largely bred out of the black market supply precisely because prohibition optimises for potency rather than balance. The plant, as it’s found in nature, comes with its own safety mechanism. We have been removing it.

A note on reading the harm rankings honestly

A careful reader will notice an apparent contradiction: Professor Nutt’s ranking places ketamine at 15 and cannabis at 20, meaning cannabis scores as more harmful overall. Yet, I am treating ketamine with far more caution. Why?

The score in The Lancet paper is an aggregate across sixteen different criteria, split between harms to the individual and harms to society. Cannabis scores higher overall largely because of its massive scale of use. When tens of millions of people use a substance, even modest individual or economic harms multiply into a significant societal footprint. It’s common combination with tobbaco also makes cannabis more harmful that it is by itself, particularly when harm reduction practices around THC/CBD ratio are followed.

Ketamine’s lower aggregate score reflects its smaller societal and economic burden, but it should not be confused with individual safety. For a regular user, the acute physical and psychological risks of ketamine can be profoundly high, as more recent data is starting to show.

This distinction matters enormously today for three reasons:

• Ketamine has been increasingly embraced as part of the psychedelic renaissance - given its mind-altering properties and genuine efficacy as a treatment for depression - while cannabis, despite its own changing legal landscape, rarely carries that same therapeutic halo. This framing shapes how people assess risk, sometimes leading recreational users to underestimate ketamine’s dangers.

• The Lancet data is a 2010 snapshot. Since then, recreational ketamine use has spiked, and with it, we have seen an increase in severe dependency, devastating bladder damage and a sharp rise in ketamine-related fatalities.

• It is also telling that while both substances are now used in medical settings, cannabis is considered safe enough to be taken at home, while ketamine requires supervised clinical administration - a distinction the recent experiment of mail-order ketamine in some US states has already begun to illustrate, with cases of serious harm emerging as a result.

The ranking is a scientific paper and a masterclass in population-level data - a compass, not a final verdict for individual behavior. Like any map, it requires translation on the ground, and that is part of what we are building here.

The Lineage We Forgot

We tend to think we need to travel to the Amazon to find a tradition of conscious psychedelic use. But we have our own Western lineage - and it has always included women.

Psychedelic Mysteries of the Feminine, edited by Maria Papaspyrou, Chiara Baldini and David Luke, is one of the most important and least discussed books to emerge from the current psychedelic renaissance. [5] It brings together scholars, practitioners and artists to recover a history that has been largely written out of the dominant narrative: the central role of women in ecstatic and psychedelic traditions across cultures and centuries. From the Maenads of Dionysian cult worship in ancient Greece and Rome, to the mystery cults of Minoan Crete, to the Eleusinian Mysteries where ergot-based psychedelics may have been central to the ritual - women were not peripheral to these traditions, they were often the heart of them. The suppression of these practices by patriarchal authority was explicitly political: the Roman Senate’s ban on the Bacchanalia in 186 BC was about was control, not about safety.

It is worth noting, however, that while these ancient Greek and Minoan lineages are recovered history, the Amazonian and Mesoamerican traditions of women as medicine keepers are present-tense. They are the most continuous living lineages we have, surviving intact despite centuries of colonial pressure.

Recovering our own Western lineage is not meant to diminish these living indigenous traditions, whose knowledge has been central to the psychedelic renaissance - and whose communities have received far too little in return. Too often, indigenous wisdom has been extracted, repackaged, and profited from without credit, consent, or reciprocity. Both histories deserve to be told, but the Western lineage should be recovered alongside those traditions, not as an alternative to them. What it offers is a reminder that this is not a foreign import - it is a thread that runs through our own history, suppressed rather than absent.

A Note on the Unknown

A simple principle of harm reduction is this: avoid substances that are younger than you.

Substances like 2-MMC, 3-MMC and synthetic cannabinoids carry mostly unknown long-term risk profiles and poor meaningful safety data. When researchers first began mapping this landscape, 236 novel psychoactive substances (NPS’s) had been identified globally in 2012 - a number that ballooned to over 830 by 2021, with new compounds appearing at roughly two per week. [9] Classic psychedelics, MDMA and cannabis have decades (or centuries) of human use behind them - and the accumulated wisdom of millions of people across generations.

The fracture of that wisdom isn’t a reflection of modern psychonauts simply being more reckless than their predecessors; it is the direct, volatile byproduct of fifty years of drug prohibition. When pioneers like Alexander Shulgin were synthesizing and documenting novel compounds in the 1960s and 70s, they were working within a vastly different landscape - often with high-purity laboratory chemistry, shared community ethics, and a slower, more deliberate pace of exploration. Today, the modern NPS market is driven by unregulated black-market chemistry designed specifically to evade changing laws. In 2026, one isn’t dealing with Shulgin’s carefully calibrated lab notes; they are dealing with an aggressive, commercialized supply chain where obscure compounds are rushed to market with zero safety data.

A useful distinction rarely made is the one between a psychonaut and a pharmaconaut. Psychonaut - from the Greek psyche (mind) and nautes (sailor) - means a sailor of the mind: someone who uses substances and other tools for genuine inner exploration. A pharmaconaut - from pharmakon (drug) - is someone whose primary relationship is with the substances themselves: always curious about the next molecule, the new compound, the unexplored combination. There is nothing inherently wrong with curiosity about novel mind-altering molecules. But there is a reason we tend to trust the wisdom of someone who has spent twenty years developing a careful and deep relationship with psilocybin mushrooms more than someone who has tried forty-seven different substances and is currently very enthusiastic about a new chemical they heard about last Tuesday.

This isn’t a rigid moral judgment - it is entirely possible to develop serious, valid knowledge by exploring a vast spectrum of substances. But in practice, depth tends to produce a more reliable kind of wisdom than sheer breadth, and the distinction is worth holding. Three or four substances, known deeply and used wisely, will take you further than twenty used casually. The ocean does not reveal itself to someone who only ever paddles.

The Middle Ground

Right now, we see a polarisation in how people relate to substances. On one side: uninformed or reckless use in the pursuit of temporary pleasure - and the neurochemical, relational and emotional toll that follows. On the other: the strict decision to stop using all substances entirely, seeking well-being exclusively through contemplative and physical practices.

But there is a middle ground. Psychotherapist Charles Wininger and his wife Shelley - who spent decades exploring the intentional use of MDMA as a tool for connection and joy, and wrote about it with rare honesty in his book Listening to Ecstasy [4] - call it Serious Fun: the idea that enjoyment and pleasure, when approached with knowledge and intention, is not the opposite of growth, but a path towards it.

Using plants or concoctions, from coffee to cacti, can be approached as a deeply human practice - one that, when grounded in evidence and intention, becomes a tool for deeper connection, self-understanding and collective flourishing. The substances themselves are rarely the whole story. The container - the context, the intention, the integration - matters just as much. While this is a cornerstone of psychedelic wisdom, it is equally true for our everyday relationships with all psychoactive compounds.

This Substack is where I will keep building the map - one substance, one context, one honest conversation at a time.

The next post will go deeper into the territory we have only sketched here: the role of context, set and setting, and the differences between taking mushrooms on a festival, in a forest and at home. If that sounds useful, follow along.

Further Reading

Mike Jay — High Society: Mind-Altering Drugs in History and Culture The broadest and most readable cultural history of human drug use. Jay’s central argument — that every society in recorded history has used psychoactive substances — is the intellectual foundation this publication stands on. Essential first reading.

David Nutt — Drugs Without the Hot Air The most accessible account of the science behind drug harm by the pharmacologist who produced the landmark Lancet rankings. Nutt writes for a general audience without dumbing down the evidence. Required reading for anyone who wants to understand why the legal status of a substance tells you almost nothing about its actual danger.

Charles Wininger — Listening to Ecstasy: The Transformative Power of MDMA A psychotherapist’s careful, decades-long account of intentional MDMA use within a long-term relationship. Unusually honest, unusually well-written, and one of the few books that takes seriously the idea that pleasure and growth are not opposites.

Maria Papaspyrou, Chiara Baldini & David Luke (eds.) — Psychedelic Mysteries of the Feminine One of the most important and least discussed books to emerge from the current psychedelic renaissance. Recovers the central role of women in ecstatic and psychedelic traditions across cultures and centuries — a history that has been largely written out of the dominant narrative. Particularly relevant to anyone who assumes this territory belongs primarily to men.

Nutt et al. (2010) — Drug harms in the UK, The Lancet The peer-reviewed paper behind the harm rankings discussed in this post. Short, readable, and worth looking at directly rather than through the filter of how it has been reported. The methodology section is particularly useful for understanding what the rankings do and don’t tell you.

Adley, Jones & Measham (2022) — Drugs Venn, Drugs: Education, Prevention and Policy The paper behind the three-class framework used throughout this publication. The Drugs Venn is the most practically useful single tool in harm reduction education — this is where it comes from.

The Beckley Foundation — beckleyfoundation.org Amanda Feilding’s legacy institution. The organisation that funded and initiated some of the world’s first brain imaging studies of LSD and psilocybin, and helped build the scientific evidence base that made the current psychedelic renaissance possible. The website is a comprehensive resource for anyone who wants to go deeper into the research.

References

[1] Mike Jay — High Society / mikejay.net

[2] Nutt et al. (2010) — Drug harms in the UK, The Lancet —

https://www.thelancet.com

[3] Amanda Feilding / Beckley Foundation — beckleyfoundation.org/amanda-feilding

[4] Wininger, C. — Listening to Ecstasy — simonandschuster.com

[5] Papaspyrou, M., Baldini, C. & Luke, D. (eds.) — Psychedelic Mysteries of the Feminine — breakingconvention.co.uk

[6] Adley, Jones & Measham (2022) — Drugs: Education, Prevention and Policy — addiction-ssa.org

[7] Ly, C., Greb, A.C., Cameron, L.P., Wong, J.M., Barragan, E.V., Wilson, P.C., Burbach, K.F., Zarandi, S.S., Sood, A., Paddy, M.R. and Duim, W.C., 2018. Psychedelics promote structural and functional neural plasticity. Cell reports, 23(11), pp.3170-3182.

[8] Cohen, R., Bastos, J., Cunha, C., Marguilho, M., Sancho, A., Silva, M.J.M., King IV, F. and Castro-Rodrigues, P., 2026. Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience. General Hospital Psychiatry, 99, pp.179-190.

[9] Morgan, C.J.A. & Curran, H.V. (2012). Ketamine use: a review. Addiction, 107(1), 27–38.

[10] Mike Jay, “How Britain fell into the K-hole”, New Statesman, https://www.newstatesman.com/politics/health/2025/06/how-britain-fell-into-the-k-hole-ketamine

[11] Di Forti, M. et al. (2019). Lancet Psychiatry, 6(5), 427–436.